What would an Anthropic OpenAI Token Price War mean for HealthTech? The HealthTech Economics of the Frontier AI Token Price War: Infrastructure Commoditisation, EHR-Native Disruption and Multi Agent Margin Expansion The artificial intelligence landscape has entered an aggressive, capital-fuelled deflationary cycle driven by intense competition among frontier model providers. Backed by monumental private financing rounds, including Anthropic's Series G funding at a $380 Billion post-money valuation and rapid algorithmic optimization, API pricing for frontier reasoning models has collapsed. The hallmark of this deflationary supercycle is Anthropic's historic 67% price reduction for its flagship Claude Opus tier, which dropped input and output costs from $15.00/$75.00 per million tokens (MTok) down to $5.00/$25.00. Simultaneously, OpenAI introduced its GPT-5.5 and GPT-5.4 families, positioning its standard production workhorse, GPT-5.4, at $2.50/$15.00 per MTok and releasing highly capable, lightweight reasoning tiers such as o4-mini and GPT-4.1 Nano. Date Model Event Input Price (per 1M) Output Price (per 1M) Context Window Key Architectural Significance May 22, 2025 Claude Opus 4 Launched $15.00 $75.00 200K Legacy high-cost flagship baseline August 5, 2025 Claude Opus 4.1 Released $15.00 $75.00 200K Maintained premium pricing structure October 15, 2025 Claude Haiku 4.5 Priced $1.00 $5.00 200K Highly optimized speed-latency tier January 8, 2026 OpenAI for Healthcare Launch $1.25 $10.00 128K GPT-5.2 powered clinical-grade launch February 5, 2026 Claude Opus 4.6 Drop $5.00 $25.00 1M 67% reduction; eliminated context premium February 17, 2026 Claude Sonnet 4.6 Release $3.00 $15.00 1M Standardized 1M context at no surcharge April 16, 2026 Claude Opus 4.7 Launch $5.00 $25.00 1M High-resolution vision; new 35% denser tokenizer May 7, 2026 GPT-Realtime-2 Launch $32.00 (Audio) $64.00 (Audio) 1M Native voice reasoning with GPT-5 intelligence May 28, 2026 Claude Opus 4.8 Launch $5.00 $25.00 1M Adaptive thinking and 3x cheaper Fast Mode While headline token rates suggest uniform deflation, closer examination reveals hidden operational costs. The release of Claude Opus 4.7 introduced a new tokeniser that consumes up to 35% more tokens for identical text blocks. This means a HealthTech application processing long clinical records may experience a hidden volume premium that partially offsets the nominal price cuts. Conversely, Anthropic minimised latency penalties by releasing Claude Opus 4.8 with an adaptive thinking model and a Fast Mode priced at $10.00/$50.00 per MTok, which is three times cheaper than the Fast Mode of previous iterations. To maximise resource allocation, developers frequently deploy model routing layers through cloud providers. Cloud routing automatically shifts simpler queries to cheaper, faster models based on prompt length and task type, compressing blended request costs by 40% to 60%. Microeconomic Impact on Clinical NLP and Scribing Workflows The economics of ambient clinical documentation have been transformed by these price drops. In 2024, running an ambient clinical scribe that summarised patient encounters required processing raw speech-to-text transcripts with high-cost APIs. The microeconomic shift is clear when comparing two standard clinical scenarios across different model generations: Scenario A (Simple Scribe): Consists of a standard 3,000-token transcript, a 2,000-token standard clinical template, and a 1,000-token clinical note output. Scenario B (Complex Multi-Agent Charting): Involves a high-context synthesis ingesting a 15,000-token clinical template and a 50,000-token historical EHR chart (labs, longitudinal charts), combined with a 3,000-token live transcript, to produce a highly detailed 2,000-token note with billing suggestions. Workload Configuration Model Baseline Cached Input Volume Standard Input Volume Output Volume Cost per Encounter Monthly Cost per Clinician (400 Encounters) Scenario A (2024) GPT-4 Turbo (Unoptimised) 0 5,000 1,000 $0.0800 $32.00 Scenario A (2026) GPT-5.4 (No Caching) 0 5,000 1,000 $0.0275 $11.00 Scenario A (2026) GPT-5.4 (90% Caching) 2,000 3,000 1,000 $0.0230 $9.20 Scenario A (2026) o4-mini (Budget Reasoning) 0 5,000 1,000 $0.0049 $1.98 Scenario B (2024) GPT-4-Turbo (Flat Context) 0 68,000 2,000 $0.7400 $296.00 Scenario B (2026) Claude Sonnet 4.6 (Cached) 65,000 3,000 2,000 $0.0585 $23.40 Scenario B (2026) o4-mini (Reasoning, Cached) 65,000 3,000 2,000 $0.0152 $6.06 This financial analysis highlights the impact of prompt-caching mechanisms. In a practical clinical RAG application running on Claude Sonnet 4.6, a 50,000 token system prompt used 500 times per day would cost approximately $75.00 daily without caching. With prompt caching enabled, the initial write costs $0.19, while the remaining 499 reads cost just $0.015 each. This reduces the daily cost to roughly $7.69, saving healthcare IT systems over $24,500 annually on a single prompt pipeline. This microeconomic shift also extends to voice-based applications. The launch of GPT-Realtime-2 provides healthcare systems with real-time, simultaneous translation at $0.034 per minute for translation and $0.017 per minute for streaming transcription. This combined rate of $0.051 per minute (~$3.06 per hour) is far lower than the four-figure cost of human translators or human scribes ($3,000 to $6,000 per month), enabling 85% to 90%+ gross margins for managed clinical voice startups. The Demise of the Compliance Premium and Geopolitics of Data Residency Historically, healthcare compliance served as a high-margin tollbooth for software developers. Software vendors building clinical AI solutions had to navigate expensive enterprise agreements to obtain a Business Associate Agreement (BAA) from underlying model providers. This compliance overhead often forced startups to buy premium, enterprise-only tiers or pay flat compliance surcharges ranging from $500 to $2,000 per month. The price war has effectively democratised HIPAA compliance. With the launch of OpenAI for Healthcare and the corresponding enterprise readiness initiatives from Anthropic, both model providers now offer standardized, API-accessible BAAs. These services provide native, secure environments where customer data is strictly segregated, excluded from public training pipelines, and processed under rigid zero-data-retention guidelines. By integrating HIPAA-compliant infrastructure directly into their standard token-rate billing, OpenAI and Anthropic have removed compliance as a premium gating mechanism, turning secure data processing into a highly commoditised utility. However, this democratisation introduces new geographical and financial complexities. OpenAI implemented a 10% premium surcharge for regional processing endpoints on all models released after March 5, 2026, that support local data residency. This is a crucial financial factor for global HealthTech platforms complying with GDPR in Europe or regional healthcare laws that prohibit sending patient data to US servers. Requirement Category HIPAA Compliance Framework GDPR (EEA) Compliance Framework Critical IT Procurement Questions for HealthTech Legal Contract Business Associate Agreement (BAA) required Data Processing Agreement (DPA) required Is the BAA/DPA included as standard or locked behind a custom enterprise tier? Data Residency Recommended; typically US-based Mandatory within EEA borders Does the regional endpoint trigger a 10% processing surcharge? Model Training Must be excluded under BAA Must be disclosed; requires active consent Is conversation data used to train or refine public foundation models? Retention Policy Configurable; supports zero-retention "Right to Erasure" must be supported Does the system support zero-retention pipelines for real-time triage? Data Encryption AES-256 at rest; TLS 1.2+ in transit Required at rest and in transit Are customer-managed encryption keys supported for patient databases? These compliance dynamics are central to the strategy of OpenAI for Healthcare, which launched on January 8, 2026. Powered by clinical GPT-5.2 models, this enterprise-focused platform provides secure workspaces, evidence retrieval with citations grounded in peer-reviewed medical papers, and direct integration with organisational tools like SharePoint. It has already been adopted by major health systems such as Cedars-Sinai, AdventHealth, and Memorial Sloan Kettering. To protect patient trust and regulatory boundaries, OpenAI maintains complete separation between "ChatGPT for Healthcare" (the enterprise provider tool) and "ChatGPT Health" (the consumer tool for medical records and wearables), ensuring no patient data flows into consumer-facing models. What would an Anthropic OpenAI Token Price War mean for HealthTech? Standalone Vertical Scribes vs. Native EHR Systems The structural shifts in API pricing coincide with an aggressive push by Electronic Record (EHR) vendors into the clinical AI space. Epic Systems' rollout of "Epic AI Charting" in February 2026 represents an existential challenge for standalone "scribe wrappers". Given Epic's dominant 42% share of the acute care hospital market, its built-in, native ambient clinical documentation tool, which captures encounter audio and drafts structured SOAP notes directly inside the chart for free, significantly reduces the appeal of simple, third-party transcription tools. In this highly competitive environment, standalone AI scribe vendors are experiencing rapid polarization. Basic subscription tools like Freed AI (Core at $79/month, Premier at $119/month) that function primarily as passive recorders are highly vulnerable to Epic's native charting, as clinicians quickly grow tired of manual copy-pasting and the administrative overhead of disparate systems. However, the token price war provides these third-party players with a powerful economic weapon. The extreme expansion in their gross margins, where platforms can operate at 80% to 90%+ margins using cheap underlying APIs, allows them to reinvest in deep, specialised workflows that Epic's native tool currently neglects. Vendor & Platform Class Monthly Provider Cost Native EHR Write-Back Depth Unique Value Proposition Primary Operational Risk EHR Built-In (Epic AI Charting) Free for Epic Customers Deeply Integrated (Direct EHR write-back & order drafts) Eliminates copy-paste; uses internal Epic clinical data Slower custom feature rollout; locked to Epic Enterprise Co-Pilot(Microsoft Dragon Copilot / Nuance DAX) $369–$830 Deeply Integrated (Fully embedded in Epic & Haiku mobile) Med-surg nursing workflows; 58 languages with translation Expensive; long procurement cycles (3–6 months) EHR-Agnostic Leaders (Abridge, Nabla) $100–$250 High (Epic Pal Partners; write-back available) Patient-facing after-visit summaries; high multi-speaker accuracy Squeezed between free native tools and high-end enterprise systems Full-Stack Automation(DeepCura) Custom Enterprise High (SMART on FHIR and FHIR R4 standard APIs) Automates history, diagnostics, prior authorisations, billing Complex setup; dependent on external API stability Self-Serve SMB Scribes (Vero, Twofold Health) $49–$89 Low (Requires manual copy-paste or extensions) Vero Chat inline editing; immediate same-day setup Highly vulnerable to commoditisation by free tools Despite its aggressive tiered pricing starting at an advertised thirty-nine dollars monthly, simpler platforms face significant clinician dissatisfaction. Practitioners report that accuracy falls sharply outside primary care, with specialties such as orthopedics and psychiatry requiring weeks of manual templates adjustments to master basic medical vocabulary. Clinicians frequently experience a feeling of being nickel-and-dimed, as essential features like ICD-10 coding, clinical visit summaries, and automated referral letters are locked behind premium tiers, effectively raising their real operating costs. Furthermore, these platforms suffer from processing delays during peak clinic hours, with note generation times ballooning from seconds to up to five minutes. Conversely, advanced players are using cheap APIs to build full-stack clinical automation. For instance, DeepCura uses FHIR R4 APIs and the SMART authorisation framework to automate the entire clinician workflow. Before an encounter begins, its Patient History agent pulls a patient's complete cross-department clinical record via FHIR, generating a concise clinical summary that saves providers up to six minutes of navigation time per patient. Other platforms like Vero use conversational edit windows, allowing clinicians to make natural-language edits directly in the note interface. By utilising the lower token rates of the price war, these platforms can process extensive clinical data and run complex reasoning chains for pennies per encounter. Clinical Accuracy, Hallucination Reductions and Model Selection Benchmarks The microeconomics of the price war cannot be isolated from clinical accuracy. Deploying cheaper models is counterproductive if it increases clinical risk through hallucinations. OpenAI and Anthropic have taken distinct architectural approaches to address this balance. OpenAI's GPT-5 family focuses on versatile reasoning, using reinforcement learning and thinking modes to reduce hallucination rates to 1.6% on HealthBench. However, physicians report that GPT-5 can write in an overly confident tone, even when discussing clinical uncertainties. Conversely, Anthropic's Claude 4 reflects an alignment-first approach. Claude is structured to refuse unsafe completions and walk the user through its reasoning process. This academically cautious posture is highly valued in clinical settings, particularly for summarising long, complex medical journals or drafting sensitive referral letters. Clinical Metric & Evaluation Benchmarks Claude 3.5 Sonnet Claude Opus 4.1 GPT-4o GPT-5 / GPT-5 Pro MURA Anatomical Recognition Accuracy 57.0% No Data No Data No Data ROCOv2 Anatomical Region Accuracy 85.0% No Data No Data 78.0% (GPT-4-Turbo) MURA Fracture Detection Accuracy Low Accuracy No Data 62.0% No Data GPQA Graduate-Level Reasoning Score No Data ~80%+ No Data Near-Perfect Medical Hallucination Rate (HealthBench) ~38.0% (Sonnet 4.6) No Data No Data 1.6% [cite: 30] SWE-Bench Verified Coding Agent Accuracy 72.0% - 80.0% ~78.0% No Data 88.6% (Opus 4.8) These clinical accuracy benchmarks highlight that neither OpenAI nor Anthropic provides a universal solution for every clinical task. Claude 3.5 Sonnet achieves superior consistency and anatomical recognition, making it ideal for processing multi-page radiological reports or complex visual inputs. Conversely, OpenAI's GPT family excels at logical precision and tool use, making it the preferred engine for medical calculations, coding and structured data queries. Given that current error rates remain significant outside structured pipelines, completely autonomous clinical AI integration without human-in-the-loop oversight is not yet feasible. Second and Third Order Market Implications The primary impact of the token price war is the transition from simple dictation wrappers to highly complex, multi-agent clinical networks. In the previous high-token-cost environment, developers were forced to optimise pipelines for token conservation, limiting the use of agentic reasoning loops. Today, cheap reasoning tokens allow developers to construct multi-agent clinical systems that execute clinical audits, cross-reference historical charts, and suggest billing codes in parallel. For instance, an encounter can be processed through a low-cost model like GPT-4.1 Nano to handle real-time PHI de-identification, passed to Claude Sonnet 4.6 for clinical summarisation, and audited for safety and drug interactions using Claude Opus 4.8, all for a fraction of a cent. The broader healthcare landscape is undergoing an accelerated shift from passive pilot environments to fully integrated clinical infrastructure. This transition is defined by the convergence of agentic workflow managers and universal ambient listening, both of which are rapidly becoming baseline standards across medical practices. Rather than serving as isolated tools, these models are integrated directly with local databases, facilitating real-time clinical quality checks, suggesting correct ICD-10 and CPT billing codes, and automatically preparing prior authorisation drafts to streamline clinical workflows. Finally, the price war is altering the capital dynamics of HealthTech investments. In the early phases of healthcare AI, startups spent a massive proportion of their venture capital on raw API compute costs, suppressing gross margins. The collapse in token pricing has expanded gross margins for vertical SaaS platforms to between 70% and 85%+, reallocating venture capital toward clinical validation, proprietary EHR integrations, and deep workflow optimisations. The ultimate value in healthcare AI has shifted from raw model access to the workflow integration layers that make these models useful to clinicians. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 12th June 2026 European HealthTech has seen a massive surge in specialised AI deployments and notable funding rounds this week, particularly focusing on optimising operational workflows, surgical intelligence and deep-tech medical solutions. Here are the key developments shaping the ecosystem right now. Funding & Expansion Boosts 01Health Secures $15M Series A: The UK-based HealthTech platform closed a major round to aggressively scale its specialist healthcare infrastructure. Thena Capital Launches £45M Debut Fund: Led entirely by female general partners, the firm closed its initial fund aimed at backing up to 25 early-stage healthcare and MedTech startups, with a heavy emphasis on how AI will transform clinical pathways. OurMind Lands €2.1M: The Dutch startup raised new capital specifically to scale its AI-driven platform designed to alleviate heavy administrative workloads from burnt-out clinical staff. Surgical and Operational AI Take Center Stage The narrative this week is strongly focused on highly niche, practical artificial intelligence applications rather than broad LLMs. Uncovr Raises $7M for Surgical AI: This startup secured fresh capital to build out dedicated AI infrastructure for operating theatres. Rather than diagnosing, its models focus on clinical documentation and workflow intelligence to automate post-op paperwork for surgeons. TurnUp Tackles Practice Efficiencies: Based in Ghent, TurnUp raised €2 million for an intelligent system designed to drastically reduce "no-shows" and last-minute cancellations for dental and medical practices across Europe. Nanordica Medical Raises €1.6M: The Estonian MedTech firm took home new funding to fast-track its advanced, antibiotic-free chronic wound care treatment, targeting the massive European medical logistics market. Regulatory Alignment & Scale The tail-end effects of the dual consolidation of the EU AI Act and Medical Device Regulations (MDR/IVDR) continue to dominate operational roadmaps. Medical software developers across the continent are seeing stricter enforcement regarding data quality and human oversight. Because of this, standard security frameworks like SOC 2 are rapidly transitioning from "nice to have" to a strictly non-negotiable entry requirement for any startup trying to integrate data directly into European hospital Electronic Health Records (EHRs). >>>> The European MedTech sector has experienced a highly active week, marked by major growth funding, critical legislative pushback over AI medical regulations, and a substantial shift in the UK's regulatory framework to attract global hardware innovation. Here are the biggest headlines driving the industry this week. Funding & Market Growth A newly released sector report by Tech.eu highlights that capital is concentrating into larger, highly commercialized rounds—specifically in the UK (€2.5B), Switzerland (~€1.0B), and Finland (€881M). Semble Secures £30M Series C: The London-based medical tech platform closed a massive growth round led by European growth investor Revaia (with Partech and Octopus Ventures). Semble operates an open, interoperable clinical platform that connects disjointed healthcare tech systems. The capital will fund its expansion into France and larger European healthcare groups. EU Directing €11.5M to DeepTech Therapeutics: The EU Grants Funding portal highlighted a major €11.57 million allocation explicitly targeting companies scaling high-readiness (TRL 6–8) solutions in advanced therapeutics and the secondary clinical use of interoperable health data. The AI Act & MDR "Parallel Regulatory" Clash A major point of friction reached a boiling point following a political agreement on the Digital Omnibus, which amends the landmark EU AI Act. The Conflict: MedTech Europe (the region's primary trade association) had heavily lobbied for AI-enabled medical technologies to be governed strictly under existing sector-specific medical rules. Instead, the final deal confirms that AI medical devices will remain subject to overlapping, parallel compliance requirements from both the AI Act and the Medical Devices Regulation (MDR). The Backlash: Industry leaders expressed deep disappointment, stating it adds "an unnecessary layer of complexity" to an already heavily strained framework. The industry is currently mobilizing to pressure the EU to simplify these overlapping rules, which the EU Parliament projects could save the industry up to €3.3 billion annually in wiped-out administrative bloat. EMA Innovation Pilot: In a positive regulatory turn, the European Medicines Agency (EMA) launched an innovative device pilot program for Class III and implantable devices, which industry experts are praising as a precursor to a formal, US-style "breakthrough device" pathway. The UK Proposes the "International Reliance" Pathway In response to the ongoing regulatory hurdles in mainland Europe, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published its draft Medical Devices (Amendment) Regulations 2026. The Big Shift: The draft officially introduces an International Reliance Pathway. This allows medical device manufacturers who have already secured regulatory clearance in trusted global markets (like the US FDA) to bypass redundant testing and access the Great Britain market via a drastically fast-tracked, simplified review process. The "AI Literacy" Medical Liability Threat As data from the newly released Philips Future Health Index 2026 reveals that nearly two-thirds (65%) of European clinicians have ramped up their use of medical AI to save time, a hidden legal risk has emerged. Medical device manufacturers are facing a growing threat of liability exposure due to diluted and vague EU guidelines on clinician "AI literacy." Regulatory experts warned this week that because formal training requirements have been diluted in recent legislative drafts, manufacturers are increasingly at risk if a clinician incorrectly interprets an AI device's output and causes patient harm. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

HealthTech Realignment: Why M&A Has Eclipsed the IPO and the Strategic Playbook for Founders Historically, the healthcare venture capital ecosystem celebrated a massive public market milestone: Initial Public Offerings (IPOs) accounted for an astonishing 94% of the total exit value in the sector. Today, the market faces a complete structural inversion. In the first half of 2025, mergers and acquisitions (M&A) accounted for over 94% of all digital health exits globally, establishing an unassailable dominance by volume and relegating the IPO to a historical mirage for all but a select tier of market leaders. Of the 113 global digital health exits recorded in the first half of 2025, 107 were executed through M&A transactions, whereas a mere 6 were achieved via public listings. This profound shift marks a permanent structural transition from a phase of speculative, venture-backed exuberance to one of pragmatic, highly disciplined growth. Metric Historical Paradigm (2019) Contemporary Paradigm (2025) Structural Inversion Mechanism Dominant Exit Vehicle Initial Public Offering (IPO) Mergers and Acquisitions (M&A) Shift from speculative capital-seeking to strategic consolidation. 94% Threshold Driver 94% of total exit value driven by IPOs 94.7% of all exits by volume driven by M&A Extreme public market volatility and severe multiple contraction. Primary Investor Focus Multi-year cash burn for speculative market share Capital efficiency and immediate return on investment Tightening of venture capital liquidity and rising interest rates. Default Startup Terminal State Public listing at high revenue multiples Private strategic trade sale or sponsor-backed roll-up High compliance costs, public undervaluations, and vendor stack consolidation. The Shift in Liquidity: Analysing the $13.9 Billion Exit Reality The absolute dominance of M&A is underscored by the scale of capital redeployment. Globally, digital health exits reached $13.9 Billion in 2025, driven by an accelerating venture capital liquidity crunch and systemic consolidation. This liquidity crunch is characterised by deep negative net cash flows for venture capital firms, which reached a deficit of $32.6 Billion in 2024, forcing limited partners to demand immediate, tangible cash returns. As global digital health funding fell from its speculative peak of $29.1 Billion in 2021 to $12.6 Billion in 2023, the capital required to sustain late-stage, unprofitable companies evaporated. Startups that previously relied on consecutive venture rounds to fund high burn rates have been forced to pursue M&A as a survival mechanism. This funding drought has dramatically altered early-stage dynamics. The Series A fundraising process has increasingly evolved into an M&A exit route rather than a bridge to further growth. Venture-to-venture acquisitions, where venture-backed consolidators use fresh capital to acquire venture-backed peers—now account for 27% of all M&A activity. This roll-up strategy allows early-stage companies to realise value and secure operational shelter without bearing the risk of a prolonged, capital-intensive independent runway. For the middle 70% of venture capital portfolios, which lack a viable pathway to an independent public listing, strategic trade sales and sponsor-backed acquisitions represent the only realistic route to liquidity. Exit Metric 2020 Peak 2024 Transition 2025 Realised Value Market Trajectory Global Digital Health Exit Value N/A N/A $13.9 Billion Highly concentrated around scaled platform buyouts. Global Digital Health Exits (H1) N/A N/A 113 Exits Highly consolidated, selective market. H1 M&A Transactions N/A 5% YoY Increase 107 Exits Remains the primary liquidity engine for venture portfolios. H1 IPO Listings 19% of exits 3% of exits 6 Exits Restricted to mature, free-cash-flow-positive leaders. PE Buyout Deal Value N/A N/A EUR 29.6 Billion (YTD) 276% year-over-year surge in financial sponsor activity. Total European M&A Deal Value N/A N/A EUR 31.8 Billion (H1) 87% value surge despite an 8% drop in overall deal count. US Private Placement Rebound N/A N/A $5.8 Billion (Q2) Highest aggregate private capital placement in three years. Macroeconomic and Structural Drivers of M&A Dominance The realignment of the exit environment around private transactions is propelled by a combination of technological, strategic, and financial catalysts that favour private consolidation over public exposure. Large Medtech and Biopharma Pressures The traditional buyers of healthcare innovation are facing structural business model challenges. Big Pharma continues to experience stagnating returns on internal research and development, driven by opaque tracking metrics and rising execution costs. To optimise research budgets, biopharma giants are turning to advanced, specialised software providers like Alchemy to streamline pipelines and improve R&D efficiency. Furthermore, a sweeping wave of expiring patents has stripped pharmaceutical companies of market share to generic alternatives, forcing them to find cost-savings through digital pipeline optimisation. Large medtech strategics, armed with significant capital, have shifted their focus from defensive cost-cutting to growth-oriented acquisitions. These giants are actively acquiring smaller innovators with advanced data sets, proprietary algorithms, and established clinical relationships. Systemic Operational Bottlenecks The broader healthcare ecosystem is operating under severe stress. Extreme physician overload and clinical burnout have forced health systems to seek scalable digital tools that can automate administrative workflows, clinical scheduling, and billing compliance. This need is compounded by patients becoming highly informed and taking a proactive role in their care, frequently self-diagnosing via resources like WebMD. This new breed of patient demands seamless digital integration and continuous engagement. Because early-stage startups face long development cycles, complex multi-stakeholder misalignment and high implementation costs, they are often unable to scale independently. Consequently, they look to be acquired by larger healthcare institutions and pharma conglomerates with the deep pockets and distribution networks required to navigate these long cycles. Strategic Portfolio Optimisation and Portfolio Gaps Industry giants like UnitedHealth, Amazon, and major biopharma firms are aggressively acquiring digital health companies to fill portfolio gaps in high-growth segments like telehealth, remote patient monitoring (RPM), and AI-driven diagnostics. Strategic buyers seek immediate synergies, such as integrating digital therapeutics or behavioral tools into their existing enterprise care platforms. For instance, Biogen acquired Human Immunology Biosciences, and Johnson & Johnson acquired Intra-Cellular Therapies to counter upcoming patent cliffs and expand their specialty portfolios. However, strategic buyers must navigate a highly complex regulatory landscape. The U.S. Department of Justice (DOJ) blocked UnitedHealth's proposed acquisition of Amedisys, demonstrating that antitrust hurdles remain a critical risk for large-scale consolidations, even as declining interest rates ease the financing of private deals. The Private Equity Influx and Buy-and-Build Playbooks With immense levels of dry powder, private equity (PE) firms are driving a massive consolidation of the healthtech landscape. Globally, healthcare private equity delivered a record performance in 2025, with disclosed deal value exceeding $191 Billion and surpassing the previous speculative high in 2021. Total exit value for healthcare PE jumped to $156 Billion in 2025, up from $54 Billion in 2024, with more than 40 deals exceeding $1 Billion in value. In Europe, H1 2025 healthcare M&A deal value grew by 87% to EUR 31.8 Billion, even as the total deal count fell by 8%, highlighting a sharp concentration in "mega-mergers". European PE buyout deal value surged 276% to EUR 29.6 Billion. PE sponsors are deploying buy-and-build strategies, acquiring robust clinical platforms and integrating smaller, specialized point solutions as bolt-ons to achieve operational leverage. Examples include KKR taking a 50% stake in Cotiviti, CD&R and TowerBrook's acquisition of R1 RCM, and Madison Dearborn's buyout of NextGen. Aaron DeGagne, a senior analyst for healthcare at PitchBook, notes that large public firms are continuously outpacing IPO activity by acquiring private medtech and digital health targets that have moved past outdated, inflated valuations.Alex Wakefield, Chief Revenue Officer of AcuityMD, similarly emphasises that major device manufacturers are aggressively targeting smaller innovators to expand their clinical footprint. Acquirer / Sponsor Target Company / Asset Transaction Value Strategic Rationale End-Market Segment Merck Verona Pharma EUR 9.5 Billion Patent cliff mitigation and pipeline optimisation. BioPharma / Therapeutics. Amgen Horizon Therapeutics $27.8 Billion Portfolio expansion in specialty therapeutics. BioPharma / Immunology. Siemens Dotmatics $5.0 Billion Expansion of clinical R&D software infrastructure. Clinical IT / Infrastructure. ELMO Software Rotageek £8.6 Million PE-backed exit generating a 1.5x money multiple. Workforce Management. Patchwork Health L2P Enterprise Undisclosed Integration of appraisal software with active clinical rotas. Clinical WFM / Suite. Lantum Doctors Rostering System Undisclosed Modernization of resident doctor pay and compliance. Clinical WFM / Compliance. Dexcom Nutrisense Undisclosed Convergence of biosensing, AI diagnostics, and coaching. Biosensing / Metabolic Health. Universal Health Services Talkspace Undisclosed Structural convergence in behavioral healthcare. Telehealth / Behavioral Care. Deconstructing the IPO Mirage: Case Studies in Market Correction The collapse of the digital health IPO market is a direct result of a fundamental misalignment between public market expectations and the operational realities of early-stage healthtech companies. During the 2020–2022 digital health boom, cheap capital and telehealth hype allowed companies to go public via SPACs at highly inflated valuations, despite having unproven revenue models and high cash burn rates. Pear Therapeutics: The Trailblazer Tax Pear Therapeutics went public through a SPAC but failed to survive the transition due to a severe mismatch between its cash burn and commercial adoption. Pear was a pioneer in prescription digital therapeutics (PDTs), designing software-driven interventions like reSET and reSET-O for substance use disorders, and Somryst for chronic insomnia. Despite presenting real-world evidence at ISPOR Europe 2022 showing per-patient healthcare cost reductions of $8,202 over 24 months, Pear was unable to secure broad commercial insurance coverage. The company's revenue model relied on state Medicaid programs, which provided insufficient reimbursement rates. Pear lacked the traditional commercial sales muscle of pharmaceutical companies to win over wary providers and payers.Facing a massive operating loss of $123.4 Million on just $12.7 Million in revenue in 2022, Pear laid off 9% of its workforce in July 2022 to save $28 Million. As its cash reserves dwindled, the company withdrew its financial forecasts, attempted to sell up to $300 Million in stock, and ultimately filed for Chapter 11 bankruptcy in April 2023, liquidating its assets and laying off over 90% of its remaining staff. Babylon Health and Akili Interactive: Structural Failures Babylon Health reached a peak valuation of over $2 Billion before going public via a SPAC. The company scaled rapidly but struggled with unsustainable risk-sharing primary care contracts, high customer acquisition costs, and an unproven virtual-first revenue model. In September 2023, Babylon went bankrupt and its UK operations were sold for parts. Similarly, Akili Interactive was forced to pivot away from its prescription digital therapeutics model after generating just $114,000 in revenue against $15.3 Million in expenses in Q2 2023, illustrating the commercial failure of treating software products like high-priced pharmaceuticals without the backing of established distribution networks. The 2025 Rational IPO Comeback While the SPAC-era listings collapsed, 2025 saw a highly selective IPO comeback. Five digital health companies went public: Hinge Health, Omada Health, HeartFlow, Carlsmed, and Profusa. Unlike their predecessors, these companies possessed mature financial structures, clear paths to profitability, and extensive clinical validation. Hinge Health entered the public market already free-cash-flow positive, boasting a 98% client retention rate and a technology platform that automated 95% of clinician hours for its physical therapy programs. Omada Health crossed 1 million members in Q1 2026, reporting $78 Million in revenue (up 42% year-over-year) and a GAAP gross margin expansion to 62%. HeartFlow leveraged over 3,000 peer-reviewed papers and secured direct reimbursement from Medicare and private payers for its AI-powered diagnostic platform, creating a highly defensible revenue stream. These successful listings established that public markets now demand rigorous proof of scale, high gross margins, and clinical validation, making IPOs an unrealistic target for the vast majority of startups and leaving M&A as the default exit pathway. Company / Asset Listing Mechanism Peak Market Value Primary Financial Failure / Success Driver Clinical & Reimbursement Foundation Pear Therapeutics SPAC Liquidation High R&D burn; premature public exposure; lack of pharmaceutical sales muscle. Insufficient Medicaid coverage; failed to secure commercial payer adoption. Babylon Health SPAC Bankrupt / Sold for parts High cash burn on unproven risk-sharing primary care models. Failed to prove clinical or administrative cost-savings to commercial health systems. Akili Interactive SPAC Pivot to Consumer Model Unsustainable R&D and clinical trial costs; generated just $114K revenue in Q2 2023. Failed prescription-only model; shifted to non-prescription distribution. Hinge Health Traditional IPO Trading above IPO price Profitable on a free cash flow basis; high operating margins; 98% client retention. Virtual musculoskeletal care covered by major employers and health plans. Omada Health Traditional IPO Revenue $78M in Q1 2026 (up 42% YoY) Reassurance of financial discipline; GAAP gross margin expanded to 62%. Chronic care platform backed by 29 peer-reviewed clinical studies. HeartFlow Traditional IPO Trading above IPO price defensible business built around high-growth coronary diagnostics. AI-powered diagnostic platform supported by 3,000 peer-reviewed papers. Pre-M&A Playbook for Founders: Channel Partnerships, Cloud Marketplaces and Interoperability In an environment where M&A represents the default exit, founders must shape their business around the key metrics strategic and financial acquirers care about. Deploying a channel partnership is a highly effective pre-M&A strategy, as a successful channel motion decreases the average sales cycle by 25%, whereas relying solely on direct sales increases it by 10%. Consequently, 27% of founders launch channel partnerships specifically to reduce customer acquisition costs (CAC). Commercial Timeline Alignment Startups execute channel strategies at different stages of maturity. Ciitizen engaged early with patient advocacy groups as marketing and lead-generation channels before its product was fully mature to shape development. Cedar deferred its channel motion, waiting until its fourth year to sign its first major contract to ensure its direct-sales playbook was repeatable first. Ginger established a highly structured partnership with navigation platform Accolade to rapidly scale its mental health services. Exploiting Cloud Marketplaces Cloud marketplaces operated by hyperscalers (AWS, Microsoft Azure, Google Cloud Platform) allow healthcare organisations to procure software using pre-allocated cloud spend, bypassing standard procurement friction. Founders must align marketplace selection with their primary buyer persona. Infrastructure, cybersecurity, and clinical data platforms should prioritize the AWS marketplace, leveraging its strong relationships with hospital CIOs and CISOs. Application software targeting administrative, HR, and financial operations should prioritise Microsoft Azure, leveraging its deep relationships with health system CFOs and revenue-cycle executives. Navigating Regional and Regulatory Variations The U.S. market prioritises commercial speed, rapid data integration, and the creation of "algorithmic moats" to capture high-value chronic care markets. Conversely, the European market is highly fragmented, requiring a localised approach to navigate country-specific reimbursement systems (such as the German DiGA framework). European private equity sponsors rely heavily on buy-and-build strategies, rolling up fragmented medical device manufacturers and Contract Development and Manufacturing Organisations (CDMOs). Startups operating in Europe must ensure strict compliance with GDPR and the European Union Medical Device Regulation (EU MDR). Furthermore, founders must monitor heightened antitrust scrutiny of below-threshold transactions, illustrated by the French Competition Authority's November 2025 ruling and EUR 4,665,000 fine against Doctolib for abuse of dominance. HealthTech Realignment: Why M&A Has Eclipsed the IPO and the Strategic Playbook for Founders Technical Audits and EHR Interoperability Corporate acquirers conduct thorough technical audits of a target's product architecture before committing to an acquisition. Startups must evaluated their product against key standards : Data Privacy: Compliance with US HIPAA and European GDPR, historical data breach logs, and user consent records. Information Security: Compliance with SOC 2, ISO 27001, and PCI DSS. Medical Device Regulation: Alignment with US FDA premarket notifications and European MDR post-market surveillance. EHR Integration: Integration with major electronic health record (EHR) systems like Epic, Cerner, and Allscripts. Startups should build on REST-based interoperability standards, specifically Fast Healthcare Interoperability Resources (FHIR) and HL7 connectivity protocols. To preserve corporate optionality during partnerships, founders should limit legal exclusivity and Right of First Refusal (ROFR) clauses to 30 to 90 days, tie them to clear performance milestones, and include exit clauses if sales targets are missed. Partnership Model Functional Mechanism Strategic Advantage Operational Risk Marketing Partners Top-of-funnel lead generation and referral of qualified prospects. Validates initial market demand within the partner's client base. High dependence on the partner's brand awareness; risk of low lead conversion. Co-Sale Partners Direct collaboration between the partner's and target's sales forces. Builds operational rapport and tests cultural and technical alignment. The "enablement gap"; requires full-time staff to train partner representatives. Contracting Partners Utilizes the partner's existing enterprise contracting vehicles. Eases procurement and billing; bypasses hospital purchasing friction. Potential "product drift" where the partner's preferences alter the roadmap. Cloud Marketplaces(AWS/Azure) Procurement through pre-allocated hyperscaler cloud spend. Accesses large budgets; fast procurement with CIOs and CFOs. Requires dedicated staff to manage complex billing and custom CRM workflows. Capital Structure and the Valuation Stack: Protecting the Cap Table In an exit environment where valuations have normalised from previous highs, the structural terms within a startup's capitalisation table heavily influence payout distributions. Liquidation preferences serve as a primary downside protection mechanism for investors, ensuring they recoup their capital before founders and employees receive any proceeds. The Valuation Stack and Boardroom Friction A liquidation preference dictates how proceeds from a sale are distributed between preferred stock (held by venture capitalists) and common stock (held by founders and employees). In 2025-2026, many startups are exiting below their peak valuations from 2021, creating significant tension among investors. Because different preferred share classes sit in a specific liquidation stack, often stacked in reverse order (Series D, then C, then B, then A)—late-stage investors are positioned to take most of the proceeds in modest exits. During M&A negotiations, each preferred class may vote differently depending on their place in the stack. For example, if Series D investors are guaranteed a 1x return but the exit price is just above their investment amount, they have the leverage to block earlier-stage investors from receiving any payout, creating severe boardroom friction. Liquidation Preference Structures The economic impact of liquidation preferences depends on the specific structure negotiated in the term sheet : 1x Non-Participating Preferred: The standard, founder-friendly structure. The investor receives either their initial investment back or their pro-rata share of the exit, whichever is greater, but not both. Participating Preferred ("Double-Dipping"): This structure allows investors to claw back their initial investment first, and also share in the remaining proceeds like everyone else according to their ownership percentage, significantly diluting the return for common shareholders. Multiple Liquidation Preferences (2x or 3x): Requires the startup to return double or triple the investor's original capital before any other shareholders are paid, often used in late-stage, high-risk, or distressed rounds. Capped Participation: Offers participation, but caps total investor returns at a multiple of their original investment (typically 2x to 3x) to prevent disproportionate investor returns in large exits. Exit Payout Simulation To understand the economic impact of these terms, consider a startup that raised a €2 million Seed round (1x non-participating preferred) and a €10 million Series A round (20% ownership) on a total of €12 million raised, later exiting at €20 million. Under a standard 1x Non-Participating structure, the Series A investor would convert to common stock and take 20% of the €20 million exit (€4 million), leaving €16 million to be shared among the Seed investor and common shareholders. However, if the Series A investor negotiated a 1x Participating Preferred structure, the Series A investor would claim their €10 million preference first. They would then take 20% of the remaining €10 million (€2 million), totaling €12 million. This leaves only €8 million to be shared among the Seed investor and the founders/employees, significantly reducing the common shareholders' expected payout despite the exit being nearly double the total capital raised. Liquidation Preference Structure Series A Investor Payout Seed Investor Payout Founders & Employees Payout Common Shareholder Dilution 1x Non-Participating €4.0 Million €2.0 Million €14.0 Million Standard; founder-friendly downside protection. 1x Participating €12.0 Million €1.6 Million €6.4 Million Severe; investor "double-dips" and claims 60% of the exit. 2x Non-Participating €20.0 Million €0.0 Million €0.0 Million Extreme; investor claims the entire exit; all other shareholders wiped out. 1x Participating (Capped at 1.5x) €12.0 Million €1.6 Million €6.4 Million Partial protection; cap is not reached in this scenario. Strategic Actions for Founders: Building for Trade Sales To successfully position their companies for acquisition in this M&A-dominated environment, founders and investors must evaluate their business models against six key strategic questions : 1. Is the business model Scalable? Founders must demonstrate exactly how the business will grow in the next 2 to 5 years. This requires a clear plan showing whether growth will be driven by direct sales, channel partners, or public procurement tenders. 2. Is growth Sustainable? Acquirers look for a clear path to profitability rather than unprofitable growth. Startups must document the number of enterprise deals required to reach breakeven and prove that their unit economics are improving over time. Founders should measure their performance against the SaaS "Rule of 40," which states that a company's year-over-year revenue growth rate plus its EBITDA margin should equal or exceed 40%. In highly disciplined market conditions, a healthtech firm growing at a sustainable rate of 25% with a 15% EBITDA margin presents a highly attractive, de-risked target for a strategic consolidator or a private equity platform. Outstanding public performers like iRhythm (+92% YTD), Doximity (+37%), and Sectra (+30%) demonstrate that investors heavily favour scalable, mission-critical platforms that balance growth with margin discipline. 3. Is the value proposition Defendable? Startups must define their competitive moat. Acquirers seek companies with proprietary clinical data assets, established distribution channels, unique product integrations, regulatory clearances, or long-term strategic partnerships. 4. Are there Multiple Use Cases? Founders should provide evidence of at least 2 to 5 different use cases for their products or services, supported by concrete clinical and operational case studies that prove a clear return on investment (ROI) for health systems. 5. Can the product expand into Multiple Geographies? Acquirers value products that are not restricted to a single country's healthcare system. Technology architectures must be fully interoperable with multiple electronic health records (EHRs) and clinical IT systems to facilitate rapid international expansion. 6. Can the company diversify into Multiple Industries? Founders should design their products to be flexible enough to sell outside of traditional healthcare providers, expanding their target addressable market to commercial insurers, private employers, and biopharma companies. By answering these questions early in their development, healthtech founders can transition their companies from speculative venture targets into highly attractive, de-risked acquisition opportunities, ensuring successful exits and generating essential liquidity for the venture capital ecosystem. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Oracle views healthcare as a major long-term AI opportunity Financial Performance and the Strategic Positioning of Oracle Health Oracle Corporation’s fiscal fourth-quarter 2026 financial results, announced on June 10th, 2026, reveal a corporate strategy heavily reliant on cloud infrastructure and artificial intelligence to drive its next phase of enterprise growth. The corporation achieved record quarterly revenues of $19.2 Billion, representing a 21% year-over-year expansion. This performance was underpinned by a 47% surge in total cloud revenue to $9.9 Billion, with Oracle Cloud Infrastructure (OCI) accelerating by 93% to $5.8 Billion. Remaining Performance Obligations (RPO) grew by 363% to a record $638 Billion, presenting a significant future revenue stream. This massive backlog is primarily composed of large-scale AI training and inference workloads, with prepayments and customer-supplied hardware absorbing a substantial portion of Oracle's near-term data centre expansion costs. Despite these record top-line metrics, Oracle's rapid capacity expansion has come at a high capital cost, resulting in a negative free cash flow of $23.7 Billion for fiscal year 2026. To maintain its infrastructure momentum, Oracle plans to raise approximately $40 Billion through debt and equity financing in fiscal 2027, including $20 Billion in at-the-market equity issuance. A critical component of this long-term capital allocation strategy is the monetization of its healthcare vertical. While the Oracle Health business segment, primarily comprised of the acquired Cerner assets, remains a smaller piece of the overall company today, corporate management views healthcare as a major long-term AI opportunity. Oracle expects Oracle Health to return to double-digit revenue growth in fiscal 2027, driven by a newly rebuilt, AI-powered overhaul of its patient care management platform. Financial Metric Q4 FY2026 Reported Value Full Year FY2026 Value FY2027 Projected Target Total Corporate Revenue $19.18 Billion (+21% YoY) $67.40 Billion (+17% YoY) $90.00 Billion Total Cloud Revenue $9.90 Billion (+47% YoY) $34.00 Billion (+39% YoY) Guided to 58%–64% growth in Q1 Cloud Infrastructure (IaaS) $5.80 Billion (+93% YoY) $18.10 Billion (+77% YoY) Scale approaching 1 gigawatt capacity Remaining Performance Obligations $638.00 Billion (+363% YoY) $638.00 Billion Gradual conversion through FY2030 Non-GAAP Earnings Per Share $2.11 (+24% YoY) $7.63 (+27% YoY) $8.05 Free Cash Flow Negative (Quarterly) Negative $23.70 Billion Expected positive inflection by FY2029 Oracle Health Segment Growth Low-single digits (Transition phase) Stabilizing post-acquisition Double-digit percentage growth The broader economic environment surrounding Oracle’s healthcare and enterprise applications indicates a highly resilient market for specialized software deployment. Global demand for consulting, implementation, and managed cloud services remains robust, with the Oracle services market projected to expand from $62.4 Billion in 2025 to $118.7 Billion by 2034. Notably, the healthcare vertical represents the second-largest industry segment for Oracle services, accounting for an 18.2% market share and expanding at a compound annual growth rate (CAGR) of 9.8% through 2034. This transition is further supported by a massive wave of ERP migrations, with analysts estimating that more than 65% of Oracle ERP customers globally will initiate or complete Fusion Cloud migrations by 2027. Oracle Services Market Segmentation (2025–2034) Market Share (2025) Projected CAGR (2026–2034) Key Operational Drivers By Service Type: Implementation 34.2% 7.9% Enterprise transition to Fusion Cloud applications By Service Type: Consulting 28.6% 7.2% Architecture design and multicloud integration By Service Type: Managed Services 15.4% 9.6% Convergence of autonomous databases with managed IT By Vertical: BFSI 27.4% 7.3% Legacy migration and secure financial transactions By Vertical: Healthcare 18.2% 9.8% Clinical data interoperability and AI integration By Vertical: Manufacturing 16.5% 8.2% SCM cloud adoption and predictive logistics The Next-Generation EHR Overhaul and AI-Driven Clinical Efficiencies The centerpiece of the Oracle Health revitalization strategy is a complete technical overhaul of the legacy Cerner Electronic Health Record (EHR) platform. Historically, Cerner’s Millennium architecture relied on legacy on-premises databases first engineered in the late 1990s, which often added operational complexity and heavy administrative burdens for clinical staff. In August 2025, Oracle introduced its next-generation, cloud-native EHR, built from the ground up on OCI and designed with a voice-first clinical interface. Corporate leadership asserts that embedding generative artificial intelligence directly into the EHR workflow will improve patient outcomes, lower healthcare costs, and reduce administrative burdens on doctors. The primary mechanism for reducing this administrative burden is the Oracle Health Clinical AI Agent, formerly known as the Clinical Digital Assistant. This tool leverages ambient clinical intelligence and natural language processing to listen to patient-physician encounters in real time. The Clinical AI Agent automatically drafts comprehensive clinical notes and proposes relevant next steps, such as scheduling lab tests, ordering medications, or filing follow-up patient portal communications, which are then presented to the physician for review and sign-off. By early 2026, the Clinical AI Agent had moved past the pilot phase and was deployed across more than 30 medical specialties, demonstrating a nearly 30% reduction in daily physician documentation time. Over one million clinical notes have been generated using the platform, which has recently expanded its presence internationally to address physician burnout in regions such as the United Kingdom and Canada. To quantify the operational efficiencies generated by these integrated cloud-AI capabilities, health systems have conducted trials spanning clinical, administrative, and financial domains: Clinical Documentation and Charting: Ambient listening integrations have allowed ambulatory clinics to reduce average note-generation time by nearly 30%, translating directly to reduced documentation work outside of standard clinic hours. Patient Voice and Administrative Interaction: At a university-affiliated hospital utilizing Cerner, a trial of Oracle's generative AI patient chatbot for scheduling allowed 70% of patients to complete scheduling calls entirely without human intervention, representing a significant increase over the 30% completion rate achieved with legacy Interactive Voice Response (IVR) systems. Billing and Call-Center Volume: AI billing chatbots successfully resolved approximately 50% of common patient inquiries, halving the inbound call volume directed to human billing staff and lowering administrative costs. Revenue Cycle Management: A multi-state health network migrating its Cerner billing data to OCI utilised prebuilt cloud AI models to identify coding errors, resulting in the annual recovery of $5 Million in lost revenue. Clinical Decision Support and Diagnostics: A research university deployed Oracle AI analytics on Cerner imaging data to identify early signs of sepsis, reporting a 20% reduction in sepsis-related complications. Population Health and Predictive Modeling: Researchers at the Department of Veterans Affairs (VA) utilised Cerner clinical data to build predictive AI models that identified high-risk COVID-19 patients, lowering intensive care unit (ICU) load by 15% through early, targeted clinical interventions. This multi-faceted AI approach is designed to shift EHR software from a passive record-keeping system into an active clinical assistant. To accelerate adoption, Oracle has introduced outcome-based pricing models, charging healthcare providers based on patient throughput and wait-time reductions rather than charging flat licensing fees. This pricing strategy aligns Oracle’s financial returns with the operational performance of the clinical institutions it serves. Competitive Dynamics in Clinical Informatics: Oracle Health versus Epic Systems The market for enterprise clinical informatics remains a highly concentrated duopoly dominated by Epic Systems and Oracle Health. The competitive strategies of these two entities illustrate contrasting architectural philosophies and market positioning. Architectural and Operational Feature Oracle Health (Cerner EHR) Epic Systems (AI Suite) Core Platform Infrastructure Built natively on Oracle Cloud Infrastructure (OCI) Hosted on Microsoft Azure and Google Cloud Platform Integration Philosophy "Open" multicloud approach; direct OCI model access Highly integrated, vertical system architecture Model Partners Integrates Google Gemini models directly via OCI Deeply aligned with Microsoft Azure and OpenAI (GPT-4) Proprietary Clinical Datasets Health Data Intelligence platform COSMOS Database (300M+ patient records) Primary Ambient AI Scribe Clinical AI Agent (ambient voice and note-drafting) Native AI Charting (launched February 2026) Specialised Portal Concierges Voice chatbot for scheduling and billing inquiries Emmie (patient concierge), Art (clinician), Penny (RCM) Inpatient vs. Ambulatory Coverage Next-gen AI EHR limited to ambulatory (Inpatient in 2026+) Broadly deployed across both acute and ambulatory Market and Regulatory Challenges Legacy Cerner data breach (2025) and VA delays Multiple 2025 antitrust lawsuits over data restrictions Epic Systems holds a significant market share advantage, particularly in the domestic inpatient acute care market. Epic's competitive strategy centers on tight vertical integration. To interface with Epic, third-party developers must typically work through Epic's structured integration frameworks. Epic’s generative AI features leverage its strategic partnership with Microsoft and OpenAI, utilising GPT-4 to power its clinician-facing assistant "Art," its patient-facing MyChart concierge "Emmie," and its revenue cycle assistant "Penny". Additionally, Epic's COSMOS database, containing over 300 million longitudinal patient records, allows the company to train proprietary models such as the Cosmos Medical Event Transformer (CoMET). CoMET has demonstrated strong performance in clinical decision support and prognosis prediction across dozens of distinct clinical tasks. In contrast, Oracle Health emphasises an open, multi-cloud compatible architecture. Operating on OCI, Oracle Health allows clients to access a variety of cloud-hosted AI models, such as Google's Gemini suite, directly within their secure cloud environments. However, Oracle faces a significant product gap: as of early 2026, its newly designed, AI-powered next-generation EHR is limited to ambulatory (outpatient) providers, with the acute care (inpatient) modules delayed until later in 2026. This delay leaves a substantial portion of Cerner's legacy hospital clients reliant on older, on-premises Millennium software. Furthermore, both vendors face distinct regulatory and legal challenges. Epic is currently defending against multiple antitrust lawsuits filed in 2025 by competitors like Particle Health and CureIS Healthcare, as well as the State of Texas, alleging that Epic’s data policies restrict competition and patient choice. Conversely, Oracle Health’s primary challenges stem from infrastructure migration timelines, customer satisfaction declines during the transition phase, and the security liabilities of its legacy, unmigrated systems. Drug Development, Clinical Trials and Life Sciences Integration Oracle’s healthcare strategy extends beyond clinical care into the pharmaceutical and biotechnology sectors, reflecting its belief that AI can accelerate drug development. This convergence is driven by the Oracle Life Sciences AI Data Platform, introduced in February 2026. This cloud-native platform is designed to consolidate, standardise and intelligently organise highly fragmented clinical, research, and real-world datasets into a single environment on OCI. The platform integrates real-world clinical data from Oracle’s provider network, providing researchers with access to more than 129 Million de-identified, longitudinal patient records across 230 health systems. By applying generative AI tools and specialised autonomous research agents, life sciences organisations can query these massive datasets using natural language. This infrastructure is designed to streamline critical phases of the drug development lifecycle: Site Feasibility and Recruitment: Historically, clinical trial site selection and patient recruitment have been lengthy, costly, and inefficient. Oracle's platform utilises machine learning to analyse EHR data, matching specific clinical trial protocol parameters with local patient demographics to identify high-performing trial sites and eligible patient candidates. Regulator-Grade Evidence Generation: By linking real-world clinical histories with trial data, the platform generates reliable real-world evidence (RWE) to support regulatory filings, helping researchers identify secondary therapeutic uses for approved compounds. AI-Enabled Clinical Trial Management: Oracle's new AI clinical trial systems are designed to help regulators rapidly review and approve clinical trial results, allowing patients to gain faster access to new therapies. This connects directly with the Oracle Clinical One platform, which unifies electronic data capture (EDC), randomisation and trial supply management. Pharmacovigilance and Safety Automation: Utilising technology from its historical acquisition of Relsys, Oracle's Argus Safety platform leverages AI-driven intake and signal management to automate drug safety monitoring. This platform processes over 10 Million safety cases annually, providing automated compliance monitoring from clinical development through post-market surveillance. High-Performance Computing and Molecular Modeling: Researchers leverage OCI's high-performance computing capabilities to run AI molecular design models, accelerating early-stage drug discovery and target identification. This focus on structured, end-to-end data integration contrasts with the clinical search strategies of other technology providers. While Google Cloud has focused on enhancing Vertex AI Search for Healthcare and expanding its Med-PaLM 2 medical foundation models for third-party systems like MEDITECH Expanse, Oracle's strategy relies on vertical data integration, linking its acquired clinical EHR assets directly to its enterprise life sciences and supply chain applications. Oracle views healthcare as a major long-term AI opportunity Implementation Headwinds, Security Risks and Clinical Safety Concerns The execution of Oracle Health's growth strategy faces significant challenges, including legacy technical debt, deployment delays, and operational disruptions. The 2025 Legacy Cerner Data Breach In early 2025, Oracle Health experienced a major cybersecurity incident that highlighted the vulnerabilities of legacy, unmigrated systems. Between January and February 2025, an unknown threat actor utilised stolen credentials to compromise legacy Cerner data migration servers. These servers, which predated Oracle's 2022 acquisition of Cerner, had not yet been migrated to the secure Oracle Cloud Infrastructure. The intrusion went undetected until February 20, 2025, exposing the clinical diagnoses, Social Security numbers, and treatment histories of over 100,000 patients at Munson Healthcare, with up to 80 hospitals affected nationwide. To protect the ongoing federal investigation, Oracle Health requested that affected healthcare providers delay notifying patients. This delay led to public disclosure occurring months after the breach's discovery, which raised compliance concerns under HIPAA’s reporting mandates and prompted multiple class-action lawsuits. International Implementation Outages and Delays Operational disruptions have also affected Oracle Health’s global deployments. In July 2025, the Sheffield Teaching Hospitals NHS Foundation Trust in the United Kingdom went live with an £85 Million Oracle Cerner Electronic Patient Record (EPR) system after an eight-month delay to resolve readiness issues. Despite these preparation efforts, the deployment resulted in severe system failures. Outpatient booking systems malfunctioned, patient correspondence was disrupted, and critical waiting list data became inaccessible. In the cardiology department, staff lost visibility into patient queues, causing significant anxiety for patients awaiting treatment and requiring the trust to implement an emergency recovery program to manually triage and prioritise clinical appointments. Clinical Safety Incidents and Prescription Logic Clinical safety concerns have also emerged regarding legacy Cerner software configurations. On October 14th, 2025, an Assistant Coroner in the United Kingdom issued a Regulation 28 Report to Prevent Future Deaths to Oracle Health following a clinical inquest. The report highlighted issues with the Cerner prescribing system at the Lewisham and Greenwich NHS Trust (LGT), where a duplicate checking alert functionality was not adopted when the system was introduced, allowing clinicians to override standard alerts and leading to prescribing errors. Oracle Health subsequently clarified that its Prescription Duplicate Alert Notification is a standard feature designed as a hard stop that can be overridden, emphasizing that local trust configurations and implementation choices play a critical role in system safety and clinical decision-support performance. Government Deployments and Organisational Restructuring In the United States public sector, the Department of Veterans Affairs (VA) EHR modernisation contract, a $16 Billion initiative originally awarded to Cerner—continues to face deployment delays, usability complaints, and intensive congressional oversight. Following a deployment pause in 2023 to address system safety and clinical stability, the VA has scheduled plans to resume rollout at 13 sites in 2026. These challenges occur alongside a major corporate restructuring program. This restructuring involves laying off up to 30,000 employees globally, with the Oracle Health division absorbing 8,000 to 10,000 of the cuts. This attrition has raised concerns among clinical IT executives regarding Oracle's customer support capacity and its ability to maintain high user satisfaction rankings during the transition to OCI. Strategic Synthesis and Long-Term Outlook Oracle Health's projection of double-digit revenue growth in fiscal 2027 reflects its transition from a legacy software provider to an AI-driven, cloud-native partner. The strategy of leveraging OCI to deliver ambient clinical intelligence, automated charting, and voice-driven administrative workflows has demonstrated measurable performance improvements, including a 30% reduction in documentation time and significant gains in patient engagement. By connecting clinical data with the Oracle Life Sciences AI Data Platform, the company is positioned to capture high-margin clinical research and trial optimisation business, moving beyond the traditional bounds of EHR software. However, achieving these targets will require addressing several operational challenges. The 2025 legacy Cerner data breach and the post-implementation disruptions in Sheffield illustrate the technical risks of managing complex healthcare systems. Furthermore, the ambulatory-only status of its next-generation EHR leaves Oracle's core hospital inpatient base reliant on legacy Millennium software, exposing the company to competitive pressures from Epic Systems’ integrated ecosystem. To build on its technological advantages, Oracle Health must accelerate the deployment of its next-generation acute care platform, address security liabilities in its legacy systems and ensure its ongoing corporate restructuring does not compromise clinical support or deployment safety. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The UK Healthcare Workforce Management Platform Market: Strategic Analysis, Consolidation Dynamics and 2026 Outlook The United Kingdom healthcare workforce management platform market is undergoing a profound structural transition in 2026. This evolution is characterised by a rapid shift from fragmented, manual scheduling methods toward automated, cloud-based and intelligence-driven staffing ecosystems. Facing severe cost pressures, systemic personnel deficits and an increasingly burnt-out workforce, National Health Service Trusts and private healthcare operators are adopting integrated digital platforms to optimise labour utilisation, ensure clinical compliance and foster flexible working environments. At the same time, the investment landscape is maturing. Early-stage venture capital is yielding to private equity-backed consolidations and corporate acquisitions. Market vendors are aggressively expanding their capabilities through mergers and acquisitions, integrating legacy clinical tools with advanced artificial intelligence scheduling engines to establish comprehensive clinical workforce operating systems. Market Size, Segmentation and Growth Trajectory The expansion of the UK healthcare workforce management and staffing markets reflects a broader global push toward digital health-tech deployment. Globally, the healthcare workforce management system market is projected to grow from $2.38 Billion in 2025 to $2.72 Billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.4%. Historically, this growth was driven by the increasing complexity of clinical scheduling, rising demands for optimal labor utilisation, hospital network expansions and evolving regulatory compliance requirements. In the forecast period, the market is propelled by a rising focus on cost containment, the expansion of telehealth services and growing investments in healthcare information technology infrastructure. Within the United Kingdom, the general workforce management market, encompassing retail, hospitality, manufacturing and healthcare sectors, was valued at $429.0 Million in 2024 and is projected to expand steadily, as described by the standard compound annual growth rate formula. When applied to the UK market's projected growth from $463.36 Million in 2025 to $.1001 Billion by 2035, the calculated annualised growth rate is approximately 8.01%. The software segment represents the largest component of this market, with cloud-based solutions acting as the fastest-growing deployment type. The cloud segment is projected to grow at a CAGR of 10.5% between 2025 and 2030, driven by the demand for real-time data analytics, scalability and automated scheduling tools. Parallel to the software market, the UK healthcare staffing market is expanding rapidly to cope with persistent, structural deficits in physical staff. Valued at $3,253.2 Million in 2025, the UK staffing sector is projected to reach $7,518.3 Million by 2035, growing at a CAGR of 8.8% from 2026 to 2035. The UK represents the fastest-growing regional healthcare staffing market in Europe, ahead of major continental peers such as Germany. Allied healthcare staffing was the largest revenue-generating type in 2025, accounting for 31.27% of the market, whereas Locum Tenens staffing remains the fastest-growing lucrative segment. Market Segment / Indicator Base Value (Year) Projected Value (Year) Projected CAGR (%) Strategic Significance Global Healthcare WFM Market $2.38 Billion (2025) $2.72 Billion (2026) 14.40% Fuelled by cost containment and AI adoption. UK General WFM Market $463.36 Million (2025) $1,001.50 Million (2035) 8.01% Software and cloud solutions dominate market share. UK Cloud-Based WFM Segment Active (2025) Active (2030) 10.50% Demonstrates rapid transition away from legacy systems. UK Healthcare Staffing Market $3,253.20 Million (2025) $7,518.30 Million (2035) 8.80% Driven by Brexit-related deficits and aging clinicians. The interaction between these markets is highly cyclical. As the cost of locum and temporary staffing rises, healthcare organisations are compelled to invest in sophisticated workforce management software to optimise their internal staff banks, automate shift allocation and reduce reliance on expensive external agencies. Macro Market Tailwinds and Political Catalysts The rapid adoption of workforce management platforms in the UK healthcare sector is propelled by a series of powerful operational and political tailwinds. The Push for Cost Containment and Operational Efficiency UK healthcare organizations, particularly NHS Trusts, are operating under severe budgetary restrictions. Inefficient labour allocation, manual scheduling errors and the high cost of emergency agency staffing are major sources of financial strain. Integrated workforce management platforms directly address these inefficiencies by optimising staff schedules, tracking time and attendance accurately, and facilitating the rapid booking of internal bank staff. For instance, digital rostering and internal staff bank platforms have enabled NHS Trusts to save hundreds of thousands of pounds in agency fees within months of implementation. This trend is further supported by macro-level initiatives, such as NHS Shared Business Services launching a £900 Million healthcare AI solutions framework to accelerate the procurement of advanced digital platforms. Alignment with the 10-Year Health Plan The UK Government’s 10-Year Health Plan, published on July 3rd, 2025, heavily emphasises digitisation, interoperability, and the integration of artificial intelligence to improve clinical outcomes and streamline waiting lists. Modern workforce management platforms align directly with these policy objectives. By utilising AI-driven scheduling, healthcare providers can automatically match clinical capacity with patient demand, ensuring that specialised staff are deployed precisely where they are needed most, thereby reducing surgical backlogs and emergency department waiting times. The Shift Toward Flexible, Worker-Centric Scheduling Clinician burnout and low morale are primary contributors to the retention crisis within the NHS. Outdated, rigid shift patterns often force medical professionals out of the system. Platforms that offer worker-centric features, such as mobile self-rostering, seamless shift swapping, annualised hours tracking and personalised pay options, are vital for employee retention. Giving clinicians greater autonomy over their working hours fosters a healthier work-life balance and reduces attrition. This demand for digital enablement is underscored by phase one findings of the Scottish Government's Future Medical Workforce Project. Synthesising focus groups of over 200 doctors and national surveys of more than 1,800 medical professionals, the findings highlight a profound desire among clinicians for greater information technology enablement to simplify basic administrative scheduling and make medical careers sustainable. Technological Advancements and Real-Time Analytics The integration of predictive analytics and machine learning has converted workforce management software from reactive scheduling tools into proactive operational assets. By analysing historical patient flow data, these systems can forecast future staffing requirements, preventing understaffing during peak demand periods. Real-time data visualisation allows hospital managers to monitor labour costs, check contractual compliance and identify staffing gaps instantly on consolidated dashboards. Systemic Headwinds and Key Operational Challenges Despite robust growth drivers, the UK healthcare workforce management market is constrained by significant headwinds that complicate software implementation and increase operational friction. The Acute Healthcare Staffing Deficit The underlying challenge for any workforce management system is the absolute shortage of physical staff available to be rostered. Post-Brexit immigration barriers and a declining inflow of European Union medical professionals have left the UK facing a projected shortage of more than 100,000 healthcare professionals. According to the Health Foundation UK, the UK has only 3.93 hospital doctors per 100,000 patients, which represents an extremely low density that places immense strain on the existing medical registry. This deficit is compounded by an aging clinical workforce; in the UK, approximately 20% of registered healthcare professionals are 56 years of age or older, and 10% are over 60. When the labour pool is structurally depleted, even the most advanced AI-scheduling tool cannot fully resolve clinical coverage gaps, forcing continued reliance on expensive temporary locums. Legacy System Silos and Interoperability Barriers The NHS IT infrastructure is notoriously fragmented. Many hospitals run on legacy, on-premise administrative systems that do not communicate with modern cloud-based software. Interoperability is a core challenge; transferring clinical data from job planning software, to active rostering databases and finally to the Electronic Staff Record (ESR) for payroll processing has historically required highly manual, error-prone data re-entry. Software providers that fail to prioritise open APIs and seamless NHS system integrations face significant deployment delays. Complex Regulatory and Contractual Frameworks Rostering junior doctors and resident clinicians in the UK requires adherence to highly complex, legally mandated working hours limitations, rest period allocations, and contractual pay structures, such as those outlined in the Resident Doctor’s Ten Point Plan. Designing software that can dynamically calculate complex pay rates, validate real-time contractual compliance, and prevent illegal shift patterns without requiring manual oversight is an immense technical challenge. Furthermore, tracking compliance with general Working Time Regulations and managing complex clinical schedules (including Direct Clinical Care, Supporting Professional Activities and general administrative time) requires highly specialised software architectures that general-purpose HR systems cannot easily support. Investment Climate: Venture Capital, Private Equity and Consolidation Forces The financial landscape of the UK healthcare workforce management market in 2026 is characterized by a transition from early-stage venture funding to late-stage private equity and corporate consolidation. Historically, pioneering platforms like Lantum and Patchwork Health relied heavily on venture capital rounds to fund their product development and initial NHS customer acquisition. Lantum, for example, raised a cumulative $28.2 Million across multiple early-stage and venture rounds. This included a $15.0 Million Series C/U round in March 2022 led by Finch Capital and Aman Ghei, with participation from Piton Capital, Samos Investments, ADA Ventures, LAUNCHub Ventures, Passion Capital and the Cedars Sinai Medical Center, following an earlier $7.0 Million Series A led by Simon Calver. Similarly, Patchwork Health raised a cumulative $33.1 Million in funding, including a notable £20.0 Million Series B round to accelerate its digital staff bank technology and a £3.5 Million round to combat clinician burnout. By 2026, the investment thesis has shifted toward realizing value, achieving profitability, and building comprehensive, multi-sector workforce suites. A prime illustration of this maturation is the exit of Rotageek in June 2025. Gresham House Ventures first backed Rotageek in 2018 via the Mobeus Venture Capital Trusts (VCTs), subsequently supporting the business through multiple funding rounds totalling £5.75 Million alongside co-investor Calculus Capital, who invested in 2020. In June 2025, Gresham House and Calculus successfully exited their holdings through the acquisition of Rotageek by Australian-based, private equity-backed ELMO Software (the parent company of UK SME HR leader Breathe HR). The VCTs realised a 1.5x money multiple, generating £8.6 Million in total proceeds. This exit exemplifies a broader trend where private equity-backed consolidators are actively acquiring established, mid-market UK workforce management providers with strong annual recurring revenue (ARR) to integrate advanced clinical scheduling engines into broader enterprise Human Capital Management (HCM) software suites. This consolidation is mirrored across the wider healthcare IT ecosystem, illustrated by US private equity firm TPG acquiring the prominent GP IT supplier Optum and French digital health firm Doctolib acquiring the GP IT provider Medicus. Strategic Mergers and Acquisitions in the UK Market The competitive landscape of the UK healthcare workforce management market is being actively reshaped by strategic mergers and acquisitions. Point solutions, platforms that only offer standalone scheduling, standalone appraisal, or standalone job planning, are losing viability. To win large-scale NHS Trust contracts, software vendors must provide integrated, end-to-end clinical workforce management suites. Patchwork Health’s Acquisition of L2P Enterprise Ltd In October 2024, Patchwork Health acquired L2P Enterprise Ltd, a prominent provider of medical appraisal software and the UK’s fastest-growing provider of clinical job planning software. This transaction was highly strategic; by integrating L2P’s clinical governance tools with Patchwork’s core e-Rostering and flexible staff bank platforms, the company created a unified workforce platform designed to address the needs of over 100,000 clinicians across more than 200 NHS and private healthcare organisations. At the time of acquisition, L2P’s software was utilised by over 75 NHS trusts, with 55 organisations relying on its appraisals and credentialing tools. A key technical outcome of this acquisition was the development of a "single-click" integration. Historically, translating an annual clinical job plan into active weekly roster shifts within the NHS was a highly manual, tedious administrative task. Post-acquisition, Patchwork automated this process, allowing NHS Trusts to transfer an entire validated job plan into an active roster with a single click, eliminating administrative silos and ensuring clinical deployment aligns strictly with budgetary constraints. Lantum’s Acquisition of Doctors Rostering System In February 2026, Lantum acquired the Doctors Rostering System (DRS) from Skills for Health, launching a modernised, fully interoperable product suite called InCheck. DRS had been a foundational NHS tool for over a decade, primarily used by trusts to calculate resident doctor pay and ensure contractual compliance. Lantum modernised the legacy DRS platform by adding real-time contractual validation, automated compliance checks, and a modernised user interface with an app for clinician exception reporting. Crucially, Lantum integrated InCheck with its existing proprietary AI rota generator, In-Genius. This allows NHS Trusts to automatically generate compliant individual schedules for full-time and less-than-full-time (LTFT) staff, check contractual compliance live and generate accurate payroll outputs with no manual data entry. ELMO Group’s Acquisition of Rotageek In June 2025, ELMO Group acquired Rotageek to add advanced, AI-powered demand-led scheduling to its expanding HR technology ecosystem in the UK, which already included the SME-focused platform Breathe HR. While Rotageek originally began in 2009 as a shift planning tool for NHS Accident and Emergency (A&E) departments, it had evolved to serve large, multi-site enterprise clients across hospitality, retail and entertainment, such as Pret A Manger, Lush, William Hill, Merlin, Caffe Nero, Screwfix, Nando's, Co-op (MCC) and The Entertainer. This acquisition allowed ELMO to bridge the gap between general SME HR administration and complex, enterprise-level scheduling. By combining Rotageek’s predictive scheduling algorithms with ELMO’s scale and broad HR capabilities, the group built a comprehensive platform capable of supporting organizations from frontline clinical teams to corporate head offices. The UK Healthcare Workforce Management Platform Market: Strategic Analysis, Consolidation Dynamics and 2026 Outlook Competitive Landscape and Software Offerings The competitive arena contains a mix of highly specialised clinical platforms, broad-based SME HR solutions adapting to care environments, and emerging automated time-tracking systems. Platform Ownership & Funding Key Features Target Segments Strategic Milestones Lantum VC-backed ($28.2M total) In-Genius AI rota generator, InCheck compliance engine, mobile app, exception reporting. NHS Trusts, Integrated Care Systems (ICS), Primary Care. Acquired DRS from Skills for Health (Feb 2026) to automate payroll validation. Patchwork Health VC-backed ($33.1M total) e-Rostering, Collaborative Banks, Agency Manager, Appraisals, Single-Click Job Planning. NHS Trusts, Foundation Trusts, Regional ICS-wide banks. Onboarded 17 new NHS partnerships within 8 months of L2P acquisition. Rotageek Subsidiary of ELMO Group (Acquired June 2025) Demand-led scheduling algorithms, auto-rotas, workforce analytics, HRIS integration. Mid-to-Large Enterprise Retail, Hospitality, and Healthcare. Exited Gresham House VCTs at 1.5x multiple; integrated with HR Acuity in March 2026. HealthRota Bootstrapped (No funding raised) Usability-focused e-rostering, e-job planning, Locum Module, Personalised Pay, self-rostering. NHS Trusts, specialized clinical departments. Proven agency cost savings of £400k in 6 months at Sussex; Dorset junior doctor payroll. BrightHR Subsidiary of Peninsula Group SME HR admin, absence tracking, Blip clock-in app, 24/7 employment law and safety advice. GP Practices, Care Homes, Private Clinics, general SMEs. Distributed via Q Care Group partnership; handles GP trainee & clinician holiday scheduling. TimeTally Independent Mobile-based shift tracking, hourly/overtime auto-calculations, break tracking, WTD compliance. Care Homes, Domiciliary Care, Private Clinics, GP practices. Zero app download mobile tracking designed for high-turnover care environments. Lantum Lantum operates as an online, end-to-end clinical workforce management platform designed specifically for primary care, Integrated Care Systems (ICS), and NHS Trusts. Under the leadership of CEO Melissa Morris, Lantum has positioned itself as a critical operating system for healthcare staffing. The platform's primary competitive advantage in 2026 is its highly automated, compliant ecosystem driven by the combination of its In-Genius AI rota generator and the newly launched InCheck compliance tool. Lantum focuses on eliminating administrative friction, providing automated resident doctor contract validation, real-time pay calculation, and direct interoperability with NHS clinical systems. Patchwork Health Founded by clinicians Dr. Anas Nader and Dr. Jing Ouyang, Patchwork Health is built specifically around the philosophy of worker-centric flexibility and borderless staffing. The platform offers an expansive product suite including e-Rostering (Rota), Bank & Collaborative Bank, Agency Manager, Job Planning, Appraisals, and Patchwork Insights. Patchwork's primary differentiator is its pioneering work in regional "collaborative staff banks". By allowing multiple NHS Trusts within an Integrated Care System (ICS) to pool their temporary staff resources into a single digital bank (such as the North West Doctors in Training Collaborative Staff Bank), Patchwork enables borderless clinical working, significantly increasing shift fill rates while saving the NHS over £120 million to date. Rotageek Evolving from Chris McCullough's initial smart scheduling tool for A&E departments, Rotageek uses intelligent algorithms to build demand-led rotas. These algorithms analyze operational variables to generate optimized staffing schedules, reducing manual administration, cutting labor costs, and maximizing shift efficiency. Now operating under the ELMO Group, Rotageek leverages corporate scale to deliver enterprise-wide scheduling. This positioning makes it a strong competitor for organizations requiring highly analytical scheduling across mixed portfolios of healthcare, retail, and corporate operations. HealthRota HealthRota is a highly specialized, cloud-based e-rostering, e-job planning, and locum management platform tailored specifically for NHS Trusts and clinical departments. Founded by software developers with family members working in the NHS, HealthRota is designed to replace complex, departmental Excel spreadsheets with highly customisable, real-time digital rotas. The platform utilises a usage-based fee model and has remained highly competitive without raising institutional venture capital. HealthRota is a pioneer in annualised hours tracking and clinical self-rostering, helping prominent clients like University Hospitals Sussex NHS Trust and Gloucestershire Hospitals NHS Foundation Trust optimize staff utilization, manage junior doctor personalized pay, and cut agency costs. The platform's efficacy is demonstrated across several NHS environments. At University Hospitals Sussex NHS Trust, HealthRota's annualised approach to doctors' rotas resolved long-standing department scheduling bottlenecks. At Dorset HealthCare University NHS Foundation Trust, the platform’s flagship Personalised Pay feature solved the complex, dynamic compensation structures of junior doctors. Furthermore, Buckinghamshire Healthcare NHS Trust utilised HealthRota's rapid deployment capability to roll out a crisis-response e-rostering solution within three days, delivering sustained, long-term scheduling improvements. In another clinical evaluation, HealthRota’s automated scheduling enabled a major NHS Trust to save £400,000 within six months by dramatically reducing agency staffing reliance. BrightHR BrightHR is a subscription-based HR software platform designed for small-to-medium enterprises (SMEs). Led by CEO Alan Price as a subsidiary of the Peninsula Group, BrightHR is highly successful in the broader healthcare ecosystem, supporting private clinics, dental practices, GP surgeries, and residential care homes. BrightHR simplifies fundamental HR administration, including holiday booking, sickness tracking, document storage, and employee clocking-in via its mobile application, Blip. Its primary differentiator is its packaging of software with 24/7 employment law and health & safety advice, providing essential compliance protection for independent healthcare providers. Strategic Partnerships and Ecosystem Integration Interoperability and ecosystem connectivity are vital for securing long-term contracts in the highly regulated UK healthcare market. Isolated systems increase administrative friction, driving vendors to establish deep partnerships and product integrations. Patchwork Health’s rapid commercial growth is a direct result of this integrated approach. Following its late 2024 acquisition of L2P, Patchwork secured 17 new NHS partnerships within an eight-month period, including major healthcare providers such as Barts Health NHS Trust, Croydon Health Services NHS Trust, and Cambridge University Hospitals. By integrating L2P’s appraisal and job planning features directly with its core rostering and digital bank modules, Patchwork provided an end-to-end workforce management experience that eliminated operational silos, making its platform highly attractive to resource-constrained trusts. Strategic integrations are also bridging the gap between operational scheduling and wider corporate compliance. In March 2026, HR Acuity (a leader in employee relations case management software) announced a strategic partnership with ELMO Software’s UK business and its scheduling platform, Rotageek. This integration automatically syncs demographic and job data from the ELMO platform into HR Acuity, allowing organisations to document, track, and investigate workplace issues directly alongside employee shift schedules. By moving sensitive employee relations data out of generic spreadsheets and linking it to real-time scheduling tools, healthcare and retail operators can identify organizational risks and ensure compliance with evolving labor regulations. Furthermore, specialized distributors are expanding the reach of SME-focused workforce tools. BrightHR’s partnership with Q Care Group (QCG) serves as a key channel, allowing care homes and domiciliary care agencies to access BrightHR’s suite of absence management, clocking-in, and health & safety compliance tools at preferential rates, integrating legal protection directly with daily workforce administration. Strategic Recommendations and 2026 Market Outlook The UK healthcare workforce management platform market in 2026 has reached a high level of operational complexity, requiring clear strategies from health-tech providers, NHS executives, and investment firms. Point solutions are rapidly becoming obsolete, replaced by unified platforms that integrate clinical job planning, e-rostering and flexible staff bank scheduling into a single-pane-of-glass interface. This structural evolution suggests several key directions for the sector: For NHS Trust and Integrated Care System (ICS) Leadership: Prioritizing interoperability is essential. To reduce administrative overhead and manual double-keying of data, clinical leaders should seek software suites that offer validated "single-click" integrations, such as those linking clinical job plans directly to live rotas. Transitioning from static schedules to dynamic, annualised hours tracking and clinician self-rostering will prove critical to improving staff retention and mitigating the post-Brexit staffing deficit. For Health-Tech Software Developers: Sustained market success depends on deep compliance automation.Software must be capable of executing real-time contractual validation for complex clinical cohorts—particularly junior and resident doctors, without requiring manual intervention. Embedding AI-driven scheduling algorithms (such as Lantum's In-Genius or Rotageek's demand forecasting engines) as core infrastructure rather than optional add-ons will be key to helping resource-constrained trusts optimize clinical capacity. For Venture Capital and Private Equity Investors: The investment opportunity in 2026 lies in consolidation. With early-stage venture capital giving way to private equity-backed roll-ups, there is significant value in acquiring niche, high-performing clinical software tools (such as appraisals, revalidation, or credentialing) and integrating them into broader multi-sector HCM suites. Platforms that have achieved deep trust within the NHS, combined with strong annual recurring revenue, will continue to represent highly attractive targets for global software consolidators. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Channel Partnerships as a Pre-M&A Strategy in HealthTech: A Strategic Playbook for European and US Markets The healthcare technology (HealthTech) sector has transitioned from a phase of greenfield venture formation to one characterised by rapid platform consolidation. Driven by post-pandemic market corrections, rising operational costs, and regulatory evolution, strategic corporate buyers and private equity sponsors are executing aggressive platform strategies and buy-and-build consolidation programs. Globally, mergers and acquisitions (M&A) reached USD $4.6 Trillion, representing a 49% increase from prior lacklustre periods and marking the most active year for dealmaking since the 2021 market peak. Within this transaction wave, overall healthcare M&A deal value escalated by more than 60%, highlighted by a powerful return of "mega-deals" valued in excess of USD $10 Billion. This macro-consolidation occurs at a time when enterprise buyers, such as health systems, insurers and large physician networks, are suffering from severe "point solution fatigue". Exhausted by managing hundreds of disparate software vendors, these buyers are actively consolidating their technology stacks. This procurement shift has erected significant commercial barriers for early-stage HealthTech companies attempting direct-to-enterprise sales motions. To overcome these commercial bottlenecks, market-leading organisations are leveraging strategic channel partnerships as a pre-M&A mechanism. These alliances allow corporate acquirers to validate commercial viability, technical capability and cultural fit prior to committing capital to a formal transaction, while providing venture-backed targets with an efficient route to market. The Strategic Ecosystem: Sub-Sectors and Platform Integration The modern HealthTech ecosystem comprises a diverse range of sub-sectors, each requiring specialised commercial and integration strategies. At the core of the M&A advisory landscape are key segments such as mobile health (mHealth), electronic health and medical records (EHR/EMR), wearable devices, telehealth, telemedicine, over-the-counter (OTC) products, nutrition and retail pharmacies. Historically, healthcare organisations procured highly specialised point solutions from a fragmented array of vendors, resulting in siloed, non-integrated technology environments that were difficult and expensive to maintain. To resolve these maintenance challenges, the industry shifted toward monolithic, single-vendor EMRs. While these monolithic databases succeeded in standardising clinical workflow documentation, they proved highly inflexible in supporting analytical use cases and hosting external applications. In response to this rigidity, the digital health market has experienced a resurgence of integrated, "best-of-breed" point solutions. This architectural revival is facilitated by open, scalable analytics infrastructures, such as the Health Catalyst Data Operating System (DOS™), which aggregate and normalise data from proprietary source systems. By decoupling the data aggregation layer from the application layer, these open systems allow specialised point solutions to scale rapidly across the enterprise. For a pre-M&A strategy, this shift is critical: strategic corporate buyers prioritise targets whose software can integrate into open-platform architectures. This technical alignment ensures that after a transaction closes, the target's software can be scaled across the parent company's client base without requiring expensive database restructuring. The Pre-M&A Playbook: Timing, Structure and Revenue Dynamics Deploying a channel partnership strategy as a precursor to a transaction requires balancing timing, commercial structure and financial incentives. Initiating partnership negotiations too early can expose an immature startup to product drift, where a powerful partner’s preferences redirect the startup's product roadmap. Conversely, waiting too long can lead to missed market opportunities and higher customer acquisition costs. Timing and Commercial Execution Startups vary widely in when they initiate channel relationships: Ciitizen engaged with patient advocacy groups as marketing and lead-generation channels before its product was fully mature, leveraging early feedback to shape its development. Cedar deferred its channel motion, exploring opportunities in its second year but waiting until its fourth year to sign its first major contract, ensuring its direct-sales playbook was repeatable before handoff. Ginger established a highly structured partnership with navigation platform Accolade to rapidly scale its mental health services. Enterprise sales cycles are long and complex. Data indicates that HealthTech companies utilising a significant channel motion decreased their average sales cycle by 25%. In contrast, organisations relying entirely on direct-sales motions experienced a 10% increase in their average sales cycle over the same period, illustrating the impact of partner-led distribution. These efficiencies are why 27% of surveyed healthcare founders cite reducing customer acquisition costs as a primary driver for launching channel partnerships. Partnership Structural Models To align incentives before a transaction, companies structure their commercial relationships across three primary models, mapped to specific phases of the customer acquisition funnel: Partnership Category Operational Mechanism Strategic Value to Pre-M&A Pipeline Marketing Partners Focus on top-of-funnel lead generation, referring qualified prospects to the target. Validates initial market demand and measures product interest within the partner's client base. Co-Sale Partners Involve direct collaboration between the partner’s sales force and the target’s reps to co-sell. Builds operational rapport and tests the cultural and technical alignment of both sales teams. Contracting Partners Rely on the partner's existing contracting vehicles to ease procurement and billing. Minimizes enterprise procurement friction and demonstrates that the software can scale through existing vendor contracts. Financial Alignment and Revenue Models For a channel partnership to succeed, the financial structure must protect the target's operating margins while providing the partner with sufficient incentive to actively promote the product. While fee-for-service or fixed commissions are used, revenue-sharing agreements are the most common financial structure in healthcare channel partnerships : Revenue Model Operational Mechanism Alignment Incentive Revenue Sharing The channel partner receives a percentage of the total contract value of the closed deal. High; directly ties the partner's financial return to the target's top-line growth. Referral Fees The target pays a one-time, fixed cash fee to the partner for every qualified lead that signs. Moderate; encourages lead volume but does not incentivise long-term customer success. Flat Deal Closure Fees The partner receives a pre-negotiated flat payment upon the execution of a customer contract. Moderate; rewards closing deals but does not account for variations in deal size or duration. Commissions Sales reps are paid a direct, variable percentage based on meeting specific sales quotas. High for individual reps; drives direct sales engagement. Operational Realities and the Enablement Gap While the strategic benefits of channel partnerships are clear, operational execution is often difficult. Data shows that while 64% of surveyed companies report that channel partners contribute to their annual revenues, only 35% have effective partner coaching and development strategies in place. This disparity represents an enablement gap that often stalls promising HealthTech innovations in perpetual pilot phases. The most significant operational challenge identified by sales teams in the field is a lack of product and brand awareness.Larger partners often have broad product catalogs, and their sales reps may default to selling familiar, high-volume products rather than learning to pitch a complex, new HealthTech solution. To overcome this, targets must invest in structured partner enablement. This includes dedicating full-time staff to partner operations, integrating shared CRM systems to track leads, and simplifying complex clinical value propositions into repeatable sales playbooks. Cloud Marketplaces: Leveraging Hyperscaler Distribution Cloud marketplaces have emerged as highly efficient channel partners for enterprise HealthTech software. These platforms, operated by hyper scalers such as Amazon Web Services (AWS), Microsoft Azure and Google Cloud Platform (GCP), allow healthcare organizations to procure software using pre-allocated cloud spend. However, cloud marketplace execution requires a distinct strategy : Sector and Buyer Persona Alignment: HealthTech companies must align their marketplace choices with their primary buyer personas. For example, cybersecurity or infrastructure-focused HealthTech systems prioritize the AWS marketplace because of its strong relationships with hospital CIOs and CISOs. Conversely, application software providers targeting administrative and financial operations prioritise Microsoft Azure, leveraging Microsoft’s deep relationships with CFO and revenue-cycle executives. Operational Readiness: Hyperscaler marketplaces impose complex billing and reporting requirements. HealthTech targets must prepare operationally by dedicating staff to manage marketplace research, billing systems, and custom CRM workflows. This ensures the target can accurately track whether a customer was partner-sourced or partner-involved. Venture Capital Lever: Startups often struggle to capture the attention of large cloud providers. Leveraging strategic venture capital connections can help clear a direct path to marketplace enablement, helping early-stage companies build relationships with hyperscaler partner representatives. Comparative Geographic Landscapes: US vs. Europe The path from partnership to M&A is shaped by the regulatory and structural differences between the US and European healthcare markets. The United States: Rapid Commercial Scaling and Algorithmic Moats The US healthcare market is characterized by a high degree of private payer concentration, large integrated delivery networks (IDNs), and a focus on reducing administrative costs. Consequently, US channel partnerships often prioritise commercial speed, customer acquisition cost (CAC) reduction and rapid data integration. The primary pre-M&A driver in the US is the creation of "algorithmic moats." US strategic acquirers look for digital health targets that can integrate clinical data, behavioural tracking, and medical hardware into a unified, automated solution. These acquisitions are often structured to capture the high-value chronic disease market, where automating clinical recommendations and tracking patient behaviors can defend a buyer's core hardware margins. Europe: Multi-Local Nuances, CDMO Roll-ups and Regulatory Enforcers The European HealthTech M&A landscape is highly active, with a strong focus on digital health, artificial intelligence, and data-driven solutions. However, Europe’s fragmented, state-funded healthcare systems require a localised approach to channel partnerships, where startups must often partner with local distributors or national insurers to navigate country-specific reimbursement policies. Furthermore, European private equity sponsors rely heavily on buy-and-build strategies, rolling up fragmented medical device manufacturers and Contract Development and Manufacturing Organisations (CDMOs) to build regional scale. From a regulatory perspective, European transactions require compliance with the General Data Protection Regulation (GDPR) and the European Union Medical Device Regulation (EU MDR). Due diligence teams must verify that any target company handling patient data or manufacturing connected medical hardware has maintained compliant audit trails and safety reporting standards. Europe is also seeing increased antitrust scrutiny of below-threshold transactions. Historically, small HealthTech acquisitions escaped antitrust review because their transaction values fell below standard filing thresholds. However, regulatory bodies are increasingly utilising abuse-of-dominance frameworks to review and sanction acquisitions deemed to have anticompetitive, market-foreclosing objectives. A prime example is the French Competition Authority's (FCA) November 2025 ruling against dominant online medical booking platform Doctolib. The FCA fined Doctolib EUR 4,665,000 for abusing its dominant position by enforcing restrictive exclusivity and tying clauses on healthcare professionals. Significantly, the FCA retroactively sanctioned Doctolib’s 2018 acquisition of its chief competitor, MonDocteur. This was the first time a regulator sanctioned a non-notifiable transaction based on the European Court of Justice’s Towercast precedent, which allows national watchdogs to review acquisitions if they are shown to prevent the emergence of a viable competitor. Channel Partnerships as a Pre-M&A Strategy in HealthTech: A Strategic Playbook for European and US Markets Case Studies: Partnership-Led Acquisitions These historical cases illustrate how structured commercial partnerships can evolve into successful cross-border M&A transactions. Case Study 1: Roche and mySugr (Austria, Germany and USA) The acquisition of Austrian digital diabetes developer mySugr by Swiss diagnostics giant Roche in June 2017 is a prime example of a partnership-to-M&A pathway. Evolution of the Relationship The relationship began in 2014 as a commercial partnership, driven by Roche's desire to pair its physical diagnostics hardware with a user-friendly digital interface. mySugr had built a mobile diabetes logbook app that integrated gamification such as a "diabetes monster" companion to improve daily compliance. In 2015, the relationship deepened when the Roche Venture Fund co-led mySugr's USD $4.8 Million Series B financing round alongside iSeed Ventures. This venture investment aligned corporate incentives and provided Roche with board-level visibility into the startup's growth and technical development. In 2016, the companies executed a major product integration, syncing Roche’s Bluetooth-enabled Accu-Chek Connect blood glucose meter directly into the mySugr app. This integration automated blood sugar logging for users. The commercial partnership was validated by strong real-world clinical data: a cohort study of 440 diabetic patients using the integrated system demonstrated a 20% reduction in average blood glucose levels and a 1.3% drop in HbA1c over six months. Transaction Execution and Integration With clear evidence of clinical and commercial success, Roche acquired 100% of mySugr’s shares in June 2017. Post-acquisition, Roche chose to preserve mySugr's corporate autonomy, maintaining it as a separate legal entity. Critically, mySugr maintained its open-platform business model, continuing to sync with competing hardware from manufacturers such as Medtronic and Abbott. This structure protected mySugr’s agile culture while allowing Roche to transition from selling low-margin hardware to delivering high-margin, bundled services. This strategy was demonstrated in Germany, where insurer VKB launched a comprehensive digital coaching and supply bundle including the mySugr Pro app, unlimited test strips, and Roche's Accu-Chek Guide meter. Case Study 2: Medtronic and Companion Medical (USA) In August 2020, Medtronic announced the acquisition of San Diego-based Companion Medical, the developer of the InPen smart insulin pen system. Algorithmic Consolidation While much of the digital diabetes market focused on insulin pumps, a massive cohort of patients continued to rely on multiple daily injections (MDIs). Medtronic's acquisition of Companion Medical was designed to capture this MDI segment by adding the InPen hardware and app to Medtronic's diabetes ecosystem. Companion Medical’s journey was backed by strategic industry capital. In 2015, the startup secured strategic backing from pharmaceutical leader Eli Lilly and Company, which was developing connected insulin delivery options. This strategic backing allowed Companion Medical to navigate the regulatory process and secure FDA 510(k) clearance for its bolus dose calculator, making it the first cleared smart pen system on the US market. Medtronic’s acquisition of Companion Medical was the final piece of an intentional, data-driven acquisition strategy: By integrating these acquired assets, Medtronic built a comprehensive digital platform capable of delivering proactive, personalized dosing recommendations across both pump and injection users. Case Study 3: ResMed and Propeller Health (USA and Europe) In January 2019, ResMed completed the USD $225 Million acquisition of Madison, Wisconsin-based Propeller Health, a pioneer in respiratory digital therapeutics. Preserving Strategic Neutrality Propeller Health developed proprietary sensors that attach to standard asthma and COPD inhalers, pairing them with an app to track medication adherence and predict respiratory flares. Prior to its acquisition, Propeller had built a robust partner network with pharmaceutical manufacturers (such as Novartis) and retail pharmacy chains (such as Express Scripts). The acquisition process began after ResMed participated in Propeller’s USD $20 Million funding round in May 2018, which also included investment from Aptar Pharma. ResMed, a leader in cloud-connected ventilators for severe Stage III and IV COPD patients, recognized that Propeller’s early-intervention platforms for Stage II and III patients would allow it to support patients earlier in their disease progression. A key aspect of this transaction was preserving ecosystem neutrality. If Propeller had been acquired by a pharmaceutical manufacturer, competing drug developers would have withdrawn their integrations. Because ResMed was a medical device manufacturer, it was viewed as a neutral partner by pharmaceutical developers. Post-acquisition, Propeller continued to operate as a standalone business unit, allowing it to maintain its pharmaceutical partnerships while leveraging ResMed's commercial infrastructure in over 120 countries. This strategy was demonstrated shortly after the acquisition closed, when Propeller launched its "My Pharmacy" integration with Walgreens, allowing patients to manage refills directly within the Propeller app. Case Study 4: Aptar Group and Voluntis (USA and Europe) In September 2021, global drug delivery and material science provider Aptar Group acquired a majority stake in French digital therapeutics (DTx) pioneer Voluntis. Structuring the Cross-Border Transaction Aptar entered exclusive negotiations to acquire 64.6% of Voluntis’s share capital from management and founding shareholders at a price of €8.70 per share, representing an aggregate valuation of approximately USD $95 Million. Following clearance from the French Ministry of Economy under foreign investment regulations, Aptar completed the initial block purchase. It then launched a mandatory cash tender offer with the French Markets Authority (AMF) for the remaining outstanding shares at the same price, ultimately executing a squeeze-out to secure 100% ownership by the end of 2021. Voluntis had developed Theraxium, an algorithmic platform for creating mobile and cloud-based applications to manage chronic conditions. Its portfolio included Insulia (a CE-marked and FDA-cleared titration app for Type 2 diabetes partnered with Sanofi and Biocon) and Oleena (an oncology symptom-management platform approved in the US and Europe). To value Voluntis’s technology assets during due diligence, Aptar’s valuation teams utilized the Multi-Period Excess Earnings Method (MPEEM), valuing the acquired technology intangible assets at USD 27.9 million and other intangible assets at USD $8.4 Million. This methodology calculated the present value of the future cash flows directly attributable to the Theraxium software platform. By merging Voluntis’s digital therapeutics platform with its physical drug delivery systems, Aptar created an integrated digital health division capable of offering global pharmaceutical developers unified therapeutic packages. Anti-Trust, Exclusivity and the Pre-M&A Due Diligence Framework Using a commercial partnership as a pre-M&A validation tool requires a structured due diligence framework to identify regulatory, financial and legal risks before a transaction is finalised. Regulatory and Privacy Compliance During the partnership phase, corporate acquirers must conduct thorough technical audits of the target’s regulatory and compliance frameworks. Due diligence teams must assess the target’s policies and historical data handling across key standards: Data Privacy: Confirm compliance with US HIPAA regulations and European GDPR requirements, reviewing historical data breaches, user consent records, and data-sharing agreements. Information Security: Audit the target's engineering standards against SOC 2, ISO 27001, and PCI DSS requirements to identify potential cyber vulnerabilities. Medical Device Regulation: For software-as-a-medical-device (SaMD) or connected hardware, audit compliance with US FDA premarket notifications and European MDR post-market surveillance and adverse event reporting systems. Managing Legal Exclusivity and Optionality While commercial partners often seek long-term exclusive distribution rights, targets should negotiate these clauses carefully. Extended exclusivity periods or aggressive Right of First Refusal (ROFR) clauses can reduce a target’s market valuation by deterring other strategic buyers from bidding. If exclusivity is required to secure the partnership, targets should limit these periods to 30 to 90 days, tie them to clear performance milestones, and include clear exit clauses if the partner fails to meet agreed sales targets. Strategic Playbook Conclusions and Recommendations For venture-backed HealthTech founders and corporate development teams, the partnership-to-M&A pathway offers a reliable mechanism to scale solutions and execute strategic exits. Recommendations for HealthTech Founders Validate Product-Market Fit First: Avoid launching complex channel partnerships too early. Ensure your product has demonstrated clear product-market fit and a repeatable direct-sales motion before committing resources to partner enablement. Focus on Real-World Evidence: Establish commercial pilots that collect concrete clinical and financial data.Demonstrating that your software improves clinical outcomes (such as reducing HbA1c or hospital readmissions) provides strong support for a premium valuation during an acquisition. Build for Integration: Utilize open, scalable API architectures and data standards. Ensuring your software can integrate into open analytics platforms makes your technology highly attractive to strategic buyers looking for modular, plug-and-play acquisitions. Protect Corporate Optionality: Avoid signing long-term exclusive distribution agreements or broad ROFRs early in a partnership. Keep your cap table and commercial agreements free of restrictive clauses to ensure a competitive bidding environment during an exit process. Recommendations for Corporate Acquirers Use Partnerships as Diligence: Implement a phased acquisition funnel. Leverage minority venture investments and commercial co-selling agreements to evaluate a target’s technology, operational scalability, and team culture before committing to a full acquisition. Preserve the Target’s Autonomy: When acquiring highly digital, consumer-facing assets, avoid immediately merging them into legacy physical hardware divisions. Maintaining the target’s brand identity, open platform architecture, and separate legal status helps protect its agile development culture and partner ecosystem. Perform Rigorous Data Audits: Conduct exhaustive pre-acquisition due diligence on the target’s data privacy practices and regulatory filings. Verifying compliance with GDPR, HIPAA, and medical device standards (FDA, EU MDR) protects the parent organization from post-acquisition liability and integration delays. Structure Balanced Incentives: Ensure that pre-M&A commercial agreements are financially balanced. Use structured revenue-sharing or milestone-based commission models to keep both parties motivated to drive growth and operational alignment. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors sponsors the Oxford MedTech Society x Google Gemini Clinical Hackathon on 13th June 2026 Nelson Advisors is proud to support the Oxford MedTech Society x Google Gemini Clinical Hackathon on 13th June 2026 as a Silver Sponsor. Oxford MedTech Society x Google Gemini Clinical Hackathon Healthcare is full of problems waiting to be solved. ​Join us for a one-day hackathon bringing together students, clinicians, researchers, designers, engineers and innovators to prototype solutions for real healthcare challenges using Google Gemini. ​Across the day, participants will form teams, identify a clinical problem, develop an AI-powered concept, and pitch their solution to a panel at the end of the event. The focus is not just on building something impressive, but on creating ideas that are clinically useful, safe, scalable and grounded in real-world healthcare needs. ​No advanced coding experience is required. We are looking for people who can think critically about problems, design user-centred solutions, communicate clearly, and work well in a team. Whether you come from medicine, computer science, engineering, design, business, policy or another background, you will have something valuable to contribute. ​The day will include: ​An introduction to the hackathon challenge​ Guidance on using Google Gemini for clinical innovation​ Team formation and ideation​ Dedicated building and mentoring time​ Final pitches and judging​ Networking with students, clinicians and innovators interested in healthcare technology​ This is a chance to explore how generative AI can be applied responsibly to clinical problems, meet others interested in medtech, and turn an idea into a prototype in a single day. ​Date: 13 June 2026 Time: 09:00–17:00 Hosted by: Oxford MedTech Society and Google Gemini https://oxfordmedtechsociety.com/events_luma/ https://luma.com/qtm3we72?lm_source=embed&utm_source=website Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Bigger Cheques, Fewer Bets: Decoding Europe's €31.8 Billion HealthTech M&A Surge The Reorientation of Capital: Analytical Framework of the 'Bigger Cheques, Fewer Bets' Paradigm The European healthcare and medical technology mergers and acquisitions sector is navigating a structural transformation of lasting significance. In the first half of 2025, the market demonstrated a striking divergence in its transactional metrics: overall deal value spiked by 87% to reach €31.8 Billion, even as the total deal count contracted by 8% to 418 transactions compared to the same period in the prior year. This divergence marks a definitive transition from the speculative, volume-driven dealmaking of the pandemic-era boom to a disciplined, selective scale model. Investors and corporate acquirers have abandoned the traditional "spray and pray" methodology, under which capital was distributed broadly across early-stage point solutions, in favour of a high-conviction investment thesis colloquially termed "bigger cheques, fewer bets". This strategic recalibration is driven by a fundamental reorientation of investor priorities. Rather than chasing rapid customer acquisition and aggressive growth at all costs, capital is now heavily concentrated in a select class of maturing enterprises. These target companies must possess robust clinical validation, clear paths to profitability, sustainable unit economics, and defensible, distribution-ready platforms capable of acting as critical healthcare infrastructure. The primary driver of this capital concentration is the rise of venture capital mega-deals, defined as transactions valued at $100 Million or more. During the first half of 2025, just seven mega-deals accounted for 56% of the total venture capital investment in the European digital health space. This concentration represents a "flight to quality" in response to heightened macroeconomic pressures, including elevated capital costs and persistent inflationary concerns that surfaced in late 2024 and early 2025. While global digital health funding fell by 13% during this period, the European market demonstrated unique resilience, recording a 52% surge in total funding to reach $3.4 Billion across 182 deals, which represented a record 26% share of global funding. The market momentum experienced a selective pause and realignment in the third quarter of 2025. For instance, August 2025 recorded a sharp funding contraction, dropping to just $73 Million across three transactions. This represented a 76% decrease in investment volume and an 84% reduction in deal count compared to July 2025, when $298 Million was deployed across 19 deals. Rather than signaling a market collapse, this temporary slowdown reflects a disciplined market digestion phase, as investors focus capital on late-stage, high-conviction platforms like Verdiva Bio’s $410 Million Series A, Neko Health’s $260 Million Series B, and Windward Bio’s $200 million Series A. This "flight to quality" highlights a maturing ecosystem where capital is reallocated toward platforms with established clinical datasets, clear reimbursement pathways, and workflow integration. Market Metric YTD 2024 Baseline YTD 2025 Performance Year-over-Year Change Regional & Strategic Context Total European Healthcare M&A Value ~€17.00 Billion €31.80 Billion +87% Europe absorbed declining transaction volume from the Americas. Total European Healthcare M&A Deal Count 454 Deals 418 Deals -8% Reflects a strategic pivot toward larger platform acquisitions. Global Healthcare M&A Deal Volume Baseline Compressed -22% Global contraction driven by rising debt costs and interest rates. Global Healthcare M&A Deal Value Baseline Compressed -25% Global buyers favored smaller bolt-on assets over mega-deals. European Digital Health Venture Funding $2.24 Billion $3.40 Billion +52% Europe defied the global 13% funding decline in digital health. Average Digital Health Venture Deal Size ~$6.20 Million $18.60 Million +200% Driven by the concentration of capital into late-stage mega-deals. August 2025 Venture Deferrals Baseline $73.00 Million -76% MoM Sharp contraction representing a selective pause and realignment. Valuation Divergence and Capital Allocation Across HealthTech Verticals Valuation metrics across the European HealthTech sector reflect a highly selective market recovery. The peak average revenue multiple of 6.5x recorded in 2023 compressed to 4.8x in early 2025. Despite this downward adjustment, HealthTech valuations continue to command a substantial premium over the broader technology sector, which averaged 3.5x during the same period. For companies that have achieved positive earnings, Enterprise Value to EBITDA multiples generally stabilised between 10x and 14x as of mid-2025, representing a modest increase from the 10x to 12.5x range observed in 2024. Capital allocation is heavily stratified based on sub-sector maturity, clinical impact, and technical defensibility. The drugs and pharmaceuticals sub-sector remains the most active by volume, accounting for 42% of total European healthcare M&A activity in early 2025. In this segment, median EV/EBITDA multiples rose to 13.78x, up from 13.10x in 2024, signaling intense competition for late-stage and commercial pharmaceutical assets. Premium valuations are reserved for platforms that successfully integrate artificial intelligence, clinical workflow automation, and proprietary datasets. AI-native solutions, advanced clinical analytics, and specialised telemedicine platforms command revenue multiples of 6x to 8x, as buyers are willing to pay significant premiums to secure technological innovation and future revenue pipelines.Conversely, lower-tier assets, such as general healthcare IT solutions, unproven business-to-consumer wellness applications, basic symptom checkers, and standard telehealth platforms, face substantial valuation compression, with multiples sliding into the 2.5x to 3.5x range. To navigate the valuation gaps resulting from high capital costs and seller expectations, dealmakers are increasingly relying on alternative deal structures. Acquirers are structuring transactions with performance-based earn-outs, milestone-linked royalties, licensing agreements, and joint ventures. These mechanisms share development risks and fund ongoing innovation, particularly in volatile segments like diagnostics and digital therapeutics. Co-development partnerships are also emerging as a favored approach to mitigate regulatory and reimbursement risks, enabling platforms to secure commercial traction before completing full acquisitions. HealthTech Sub-Sector EBITDA Multiple Range Revenue Multiple Range Primary Valuation Driver & Market Context Drugs and Pharmaceuticals 13.78x (Median) Benchmark Pipeline replenishment to offset patent cliffs; 42% of total M&A. AI and Advanced Clinical Analytics Premium 6.0x – 8.0x Workflow integration, clinical validation, and proprietary algorithms. Value-Based Care & Data Monetisation Premium 5.5x – 7.0x Direct alignment with payer efficiency and secondary data use. General Healthcare IT Standard 2.5x – 3.5x Legacy software lacking clinical decision support or AI integration. Early-Stage or Unprofitable Ventures Compressed 3.0x – 4.0x valuation compression due to tight venture capital environment. Medical Imaging Platforms 14.0x (Average) Premium Strong financial sponsor interest in specialized clinical hubs. Medical Imaging Build-ups 12.5x (Average) Standard Complementary add-on acquisitions to existing imaging platforms. European Veterinary Clinics 12.0x – 15.0x Benchmark Consolidated platform sales command ~20x; clinic multiples at 10-12x. Medical Lab Testing 12.9x – 13.3x Historical High Strong historical player interest; Cerba acquired by EQT at 12.9x. Private Equity Hegemony and the Buy-and-Build Consolidation Blueprint Financial sponsors have emerged as the dominant force driving the European healthcare transaction recovery. Private equity sponsor buyouts surged by a massive 276% to €29.6 Billion, representing roughly 93% of the total €31.8 Billion M&A capital deployed in the region. This surge pushed European healthcare PE transaction volumes to a record high, surpassing the previous peak set during the low-interest-rate environment of 2021. The primary mechanism driving this private equity dominance is the execution of highly structured buy-and-build strategies. Rising interest rates and tighter debt markets have made large-scale, standalone leveraged buyouts more difficult to finance, prompting private equity firms to shift their capital toward platform consolidations. By acquiring high-quality platform assets and executing sequential, lower-multiple "bolt-on" acquisitions, sponsors can efficiently deploy significant dry powder, capture economies of scale, and arbitrage valuation multiples when the consolidated entity is eventually exited. Three landmark transactions highlight this consolidation playbook, demonstrating how financial sponsors are leveraging operational scale, geographic arbitrage, and digital integration to drive equity value: The DCC Healthcare Carve-out On April 22, 2025, London-listed, Dublin-incorporated support services group DCC plc agreed to divest its profitable DCC Healthcare division to European private equity firm Investindustrial. The transaction valued DCC Healthcare at a cash-free, debt-free enterprise value of £1.05 Billion (~€1.2 Billion equivalent), structured with £920 Million in initial cash proceeds and a £130 Million two-year deferred consideration. DCC Healthcare operates through two primary international divisions: HBI, a contract development and manufacturing organisation (CDMO) specialising in nutritional supplements and beauty products, and Vital, a value-add manufacturer and supplier of medical devices. In the fiscal year ending March 31st, 2024, DCC Healthcare recorded revenues of £859.4 Million and an adjusted operating profit of £88.1 Million, contributing roughly 13% of DCC plc's total adjusted operating profit. Investindustrial's acquisition was designed to execute an aggressive international buy-and-build strategy across the fragmented CDMO and medical device sectors. Backed by over 3,000 employees and 11 global manufacturing sites, DCC Healthcare had already completed 30 acquisitions since 2006, establishing a strong platform for future consolidation. The transaction utilised a highly sophisticated advisory architecture. Investindustrial was advised by Barclays and Moelis & Company as financial advisors, alongside Milbank, Chiomenti, and Paul Weiss as legal counsel. DCC plc was represented by J.P. Morgan as sole financial advisor, with Cleary Gottlieb and William Fry serving as legal advisors.Jamieson Corporate Finance advised the DCC Healthcare management team, led by Stephen Maxwell, Tom Burton, Alexander Wilson and Helen Briscoe, on their equity reinvestment and management incentive terms. The Mehiläinen Southern and Eastern European Roll-up Helsinki-based Mehiläinen Group, a private healthcare and social care provider owned 41.0% by funds managed by CVC Capital Partners and 38.1% by Hellman & Friedman, completed a transformative cross-border acquisition of Regina Maria in Romania and MediGroup in Serbia from private equity firm Mid Europa. The transaction, formally signed on March 29th, 2025, and concluded at the end of the year, valued the Romanian operations of Regina Maria alone at approximately $1.4 Billion. This transaction allowed Mehiläinen to establish a dominant clinical and social care footprint across Southern and Eastern Europe, expanding its Meliva-branded clinical services network. A core component of this roll-up is the deployment of BeeHealthy, Mehiläinen's proprietary digital healthcare software subsidiary. By integrating Regina Maria and MediGroup's physical clinics with BeeHealthy's electronic medical record (EMR) backbones, telehealth systems, and automated triage software, Mehiläinen is building a highly integrated, technology-enabled cross-border healthcare delivery platform. The integration of Finnish digital capabilities with lower-cost clinical networks in Eastern Europe highlights the operational synergy driving mid-market healthcare buy-and-build plays. The Sanviva Pan-European MedTech Distribution Platform On June 2, 2026, Nordic private equity firm Axcel announced the simultaneous acquisition of four regional medical technology distributors to launch Sanviva, a newly consolidated European medical device distribution network.Headquartered in Copenhagen, Denmark, Sanviva immediately covers six European countries: Denmark, Sweden, Norway, Finland, Belgium, and the Netherlands, operating with an initial workforce of approximately 60 employees. The platform was built by acquiring and consolidating four distinct regional distributors: Apodan A/S (Denmark): Operating from Hørsholm, Apodan employs 14 staff, generating an estimated $5.9 million in annual revenue. It specialises in patient hygiene, specialised wound care, compression therapy systems and clinical diagnostics. PartnerMed AS (Norway): Headquartered in Fredrikstad and led by CEO Trine-Lise Setterberg Andersen, PartnerMed has built deep commercial penetration within Norwegian public hospitals and municipal nursing homes by navigating centralised public purchasing channels. AllweCare Medical B.V. (Netherlands): Led commercially by Ton Mulder, AllweCare employs between 11 and 20 staff, with estimated annual revenues between $1.45 Million and $5.7 Million. It holds registered manufacturer status under EUDAMED Actor ID NL-MF-000004379, manufacturing and distributing proprietary brands such as ScarView and LaproCare. XboXLab AB (Sweden): Established in 2016 by Peter Blom and Christer Lidén, XboXLab focuses on in vitro diagnostics (IVD), molecular biology, and point-of-care testing systems. It operates an asset-light model, outsourcing physical logistics to Medical Log Point in Gothenburg (utilizing 1,250 square meters of warehouse space, including 310 square meters of specialized cold storage) and technical support to Nordic Service Group, which deploys over 75 field engineers across the Nordics. The consolidation was financed through Axcel Elevate I, a lower mid-market fund targeting high-growth healthcare and technology companies across Northern Europe, which held its final oversubscribed close at its hard cap of €459 Million in November 2025. Axcel’s leadership team, including Managing Partners Christian Schmidt-Jacobsen and Christian Bamberger Bro, alongside Swedish-based Partner Johan Lundén, positioned Sanviva under Group CEO Andreas von Scholten to act as a highly specialised local commercialisation partner for global medical device manufacturers and original equipment manufacturers (OEMs). The Swedish business law firm Vinge advised Axcel on the transaction, deploying a multidisciplinary team led by M&A specialists Christina Kokko, Egil Svensson, Ida Appelgren, Manon de Cooman, and Lina Björkman. Consolidated Platform Private Equity Sponsor Financing Source Acquired Operating Entities Transaction Value DCC Healthcare Investindustrial Sponsor Equity HBI (Nutritional CDMO) & Vital (Medical Devices) £1.05 Billion (~€1.2B) Regina Maria & MediGroup Mehiläinen CVC (41%) & Hellman & Friedman (38.1%) Romanian and Serbian regional hospital networks ~$1.40 Billion (Romania only) Sanviva Network Axcel Axcel Elevate I (€459M Fund) Apodan (DK), PartnerMed (NO), AllweCare (NL), XboXLab (SE) Platform Build (Funded via Elevate I) Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Regulatory Catalysts and Operational Friction Points: MDR, IVDR and the Best Buy/Current Health Case Study The acceleration of M&A and private equity roll-up strategies across Europe is heavily catalysed by escalating regulatory hurdles and the complex operational dynamics of public healthcare procurement. The implementation of the updated European Medical Devices Regulation (MDR 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR 2017/746) has profoundly altered the cost structure of the medical technology supply chain. These regulatory frameworks divide medical devices and diagnostic tests into strict risk classifications, demanding extensive clinical evaluation reports, continuous post-market clinical follow-ups, and complete supply chain traceability via EUDAMED registration. The resulting compliance overhead has created a significant barrier for small and medium-sized enterprises (SMEs). A small distributor or manufacturer with fewer than twenty employees often lacks the financial and human resources required to maintain dedicated regulatory compliance officers across multiple European jurisdictions. Consequently, these smaller players are increasingly seeking exits, selling to consolidated platforms like Sanviva that possess centralised, highly specialised regulatory task forces. This allows global original equipment manufacturers (OEMs), particularly those based in the United States or Asia, to access multiple European markets through a single, fully compliant partner, bypassing the need to establish costly country-by-country compliance operations. Furthermore, approximately 70% of medical technologies in Europe are purchased through highly fragmented, decentralized public tenders managed at the state or regional hospital level. Historically, small distributors relied on manual monitoring of localised public procurement portals, such as Doffin in Norway, Hilma in Finland, or TendSign in Sweden. Consolidated platforms are transforming this process by establishing centralised tender management offices.These specialised units utilise advanced analytics to review historical pricing data, draft sophisticated, value-based bids, and optimise margin structures. This centralised division of labor frees local clinical specialists and registered nurses to focus entirely on direct hospital and clinical relationships, boosting sales productivity across the consolidated network. The risks of expanding into clinical operations without clinical expertise are vividly illustrated by the strategic retrenchment and ultimate divestiture of Current Health by consumer electronics retailer Best Buy. Best Buy acquired the remote patient monitoring and hospital-at-home platform for approximately $400 Million in late 2021. The transaction was based on a synergistic thesis: Best Buy planned to use its massive retail logistics network and its 100,000-agent Geek Squad division as the physical infrastructure layer to deliver, configure, and install clinical monitoring hardware directly in patients' homes. Despite successful localized pilots with health systems like Geisinger and Baptist Health, the model encountered severe friction points. Managing hospital-at-home care plans is capital-intensive, requiring 24/7 clinical command centres staffed by registered nurses, sterile device sanitisation and strict medication adherence tracking. Furthermore, deploying retail personnel into clinical settings created severe regulatory and legal risks under HIPAA. Establishing data firewalls and executing formal Business Associate Agreements (BAAs) to securely transfer Protected Health Information (PHI) from home sensors to hospital electronic medical records added massive compliance costs. Compounding these operational issues was the instability of federal reimbursement. Hospital-at-home programs relied on the temporary Acute Hospital Care at Home waiver program administered by CMS. Because the United States federal government extended these waivers only in short, unpredictable intervals, healthcare systems were hesitant to invest in permanent clinical workflows, suppressing client acquisition. This friction forced Best Buy into a series of massive write-downs, including a $475 Million non-cash goodwill impairment charge on its health division in late 2024, followed by a $109 Million restructuring charge in mid-2025. Best Buy ultimately divested Current Health back to its original co-founder for an undisclosed sum, recording a final $192 Million asset impairment charge in late 2025 and marking its complete exit from the clinical enterprise space to pivot back to non-clinical active aging consumer hardware. Phase / Date Event / Strategic Move Financial Impact / Charges Operational Dynamics & Metrics Late 2021 Acquisition of Current Health ~$400.00 Million Outflow Geek Squad agents configured cellular hotspots and installed clinical hardware. Early Pilots Clinical integrations Capital-intensive setup Geisinger halved activation times; Baptist CHF 90-day survival reached 8%. Q4 FY2025 Goodwill Impairment Charge $475.00 Million Write-down Realization of high service overhead and HIPAA-related compliance friction. May 2025 Corporate Restructuring $109.00 Million Charge Laid off 161 health division employees; terminated hospital partnerships. June 2025 Startup Divestiture Undisclosed (loss-making) Divested Current Health back to co-founders Christopher McGhee & Stewart Whiting. Nov 2025 Final Goodwill Write-off $192.00 Million Asset Charge Complete termination of residual hospital-at-home clinical infrastructure. Post-2025 Non-Clinical Pivot Profitable Retail Segments Re-focused Geek Squad on Lively senior cellular phones and alert devices. Strategic Biopharma 'String-of-Pearls' and Convergence in Metabolic Health The core philosophy guiding technology acquisitions has shifted from "buying revenue" to "buying innovation" and clinical utility. Rather than acquiring commercial-stage companies with high sales volumes but easily replicated technology, strategic buyers are prioritising early-stage innovators that control clinical datasets, robust reimbursement pathways, and advanced artificial intelligence pipelines. This trend is demonstrated by a significant surge in preclinical and Phase I asset acquisitions, which accounted for more than a quarter of total healthcare M&A deal value in 2024, compared to just 8% for commercial-stage assets. This shift is driven by the looming "patent cliff" facing major pharmaceutical companies, with more than $300 Billion in potential revenue at risk due to patent expirations over the coming years. Armed with estimated cash reserves of up to $1.3 Trillion, large-cap biopharma players are executing a "string-of-pearls" strategy, acquiring highly targeted innovators to secure pipelines in oncology, immunology, and neurology. Recent multi-billion-dollar deals reflecting this trend include Johnson & Johnson's $14.6 Billion acquisition of Intra-Cellular Therapies, which secures Caplyta, a breakthrough blockbuster therapy with multi-indication potential in bipolar depression, schizophrenia and major depressive disorder, as well as Merck's $10 billion acquisition of Verona Pharma, and Sanofi's $9.5 billion purchase of Blueprint Medicines. In the digital software space, this paradigm shift is healthily illustrated by Dexcom's strategic acquisition of Nutrisense, announced during the American Diabetes Association’s Scientific Sessions in 2026. As continuous glucose monitoring (CGM) hardware has achieved near-perfect accuracy, the competitive battleground has shifted from physical biosensors to software-driven data interpretation and clinical behavioral intervention. By acquiring Nutrisense, Dexcom integrates a comprehensive metabolic health app staffed by human registered dieticians directly with its CGM platform. This allows Dexcom to transition to a high-margin subscription business model while expanding its target market from insulin-dependent diabetes patients into preventative care, weight management, and general metabolic wellness. Dexcom's metabolic expansion is supported by clinical evidence, including the CONNECT study presented at ADA 2026, which demonstrated that early CGM adoption in adults with non-insulin-dependent Type 2 diabetes significantly improved glycemic control without pharmacological escalation. It also aligns with Dexcom's over-the-counter Stelo platform, which received FDA clearance in May 2026 and launched in Summer 2026, incorporating proactive AI coaching, pattern recognition, and personalised nutritional feedback. Geographic Nuance and Structural Megatrends The European M&A recovery exhibits significant geographic variance. The United Kingdom led European digital health funding in the third quarter of 2025, deploying $409 Million, followed by Germany, France, and the Nordic countries.Conversely, Germany and Italy experienced declines in total healthcare deal value in the first half of 2025, while the Nordic region demonstrated unique strength in AI-driven oncology and preventive medicine. This is highlighted by transactions such as Helsinki-based Gosta Labs’ €7.5 Million Seed round to scale its clinical-grade artificial intelligence solutions. Regional trends during the first half of 2025 highlight further market dynamics: The Irish M&A Corridor Irish M&A activity proved highly robust, recording 236 deals worth €8.8 Billion in the first half of 2025. Mid-market transactions (valued between €5 Million and €250 Million) accounted for 88% of total volume. Key transactions included Investindustrial's €1.2 Billion acquisition of Dublin-based DCC Healthcare. Beyond manufacturing, Irish technology assets attracted substantial interest: Wolters Kluwer acquired legaltech provider Shine Analytics for €425 Million, and TA Associates acquired healthcare IT platform Clanwilliam Group for €414 Million. Additionally, private equity firm Advent International invested €153 Million in Felix Pharmaceuticals, and Germany's Merck acquired advanced manufacturing facilities in Ireland from China’s WuXi Biologics, highlighting Ireland's role as a European pharmaceutical manufacturing and IT export hub. The Romanian M&A Corridor The Romanian M&A market expanded by 45% to reach USD 4.1 Billion in the first half of 2025, driven by high-value strategic transactions and private equity activity, which rose to represent 9% of total deal volume. Mid Europa completed a trio of high-profile exits, selling clinical operator Regina Maria to Mehiläinen for USD 1.4 Billion and its logistics subsidiary Urgent Cargus to rival courier Sameday. Other significant Romanian deals in early 2025 included a USD 1.2 Billion joint venture between CVC Capital Partners and Therme Group to expand wellness infrastructure across Europe, alongside the acquisition of a 70% stake in the La Cocos retail chain by Germany's Schwarz Gruppe for USD 117 Million. These regional developments are taking place alongside the rollout of the European Health Data Space (EHDS) regulation, which was adopted in March 2025. The EHDS represents the European Union's most ambitious effort to harmonise clinical data exchange and open structured electronic health records (EHRs) for research, clinical trials, and artificial intelligence model training. This harmoniaed data framework is expected to drive data-centric acquisitions. Acquirers are actively seeking companies that manage dynamic user consent infrastructure, secure data flow networks and interoperability engines that comply with both the GDPR and the EU AI Act. Five dominant megatrends are projected to shape European HealthTech transactions through 2026: Ambient Clinical Intelligence: Acquirers are prioritising generative AI clinical scribes and ambient dictation systems to automate administrative documentation. These acquisitions are heavily focused on platforms that have achieved clinical workflow integration. Electric Medicine and Neuromodulation: Financial and strategic players are investing heavily in bioelectronic devices, brain-computer interfaces (BCIs) and non-invasive neuromodulation systems to treat chronic inflammatory, psychiatric and neurodegenerative disorders. SleepTech Integration: Transactions are accelerating at the intersection of consumer wearables and professional-grade sleep medicine. Acquirers are buying remote diagnostics platforms to integrate sleep analytics with broader cardiovascular and chronic disease remote monitoring systems. Defense MedTech and Supply Chain Resilience: Geopolitical challenges and past supply chain vulnerabilities have driven European health systems to demand secure, local medical technology manufacturing. Strategic buyers are acquiring contract manufacturing and component supply assets in stable European jurisdictions. Dynamic Consent and Data Pipeline Infrastructure: To prepare for the secondary use phase of the EHDS in 2031, buyers are securing platforms that offer secure, user-controlled data exchange pipelines. Conclusions and Strategic Advisory Recommendations The European HealthTech and medical technology mergers and acquisitions sector is poised for sustained, high-value transaction activity as the market enters a mature consolidation phase. The European HealthTech market, valued at $96.68 Billion in 2025, is projected to reach $222.22 Billion by 2030, representing an 18.11% compound annual growth rate. This growth will be underpinned by a steady pipeline of corporate carve-outs as large, listed healthcare conglomerates prune non-core assets to focus on high-margin segments, creating attractive opportunities for private equity platforms. For private equity sponsors and corporate acquirers, the current environment demands an investment strategy focused on "selective scale." Buyers should prioritise target companies that offer deep integration into clinical workflows ("workflow lock-in") and possess proprietary, clinically validated datasets. These high-quality, high-utility assets are resilient to economic volatility and continue to command valuation premiums. In contrast, acquirers should exercise extreme caution regarding consumer-facing wellness applications and unvalidated digital health solutions, which face severe valuation compression and market commoditisation. For HealthTech founders and venture-backed entrepreneurs, the strategic imperative has shifted from "growth at all costs" to "capital efficiency and clinical validation." To secure premium exits in a highly selective M&A market, companies must focus on developing clear reimbursement pathways, securing EUDAMED registration, and demonstrating concrete clinical efficacy. Leveraging alternative transaction architectures, such as performance-linked earn-outs and co-development joint ventures, can help bridge valuation gaps between buyers and sellers, enabling innovative platforms to scale despite elevated capital costs. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Wrapper or Moat? How AI Is Re-Pricing HealthTech M&A The Macroeconomic Re-Correction and the Rise of Health Tech 2.0 The healthcare technology mergers and acquisitions landscape has transitioned into a regime of industrial maturity, moving decisively past the speculative pricing cycles of the post-pandemic era. During the height of the market peak, high-growth digital health platforms were valued primarily on projected revenue expansion, frequently disregarding long-term margin profiles or underlying product defensibility. This pricing paradigm has been replaced by a rigorous valuation discipline that penalises standalone applications while heavily rewarding integrated, operationally defensive enterprise systems. This macroeconomic correction is clearly illustrated by the overall market transaction values and volumes. In 2025, global health industries M&A values rose by 46%, even as transaction volumes declined by 5%. This divergence represents a dramatic concentration of capital into high-quality, large scale assets, highlighted by 11 mega deals that closed during the year. Furthermore, roughly 70% of total transaction value in 2025 originated from fewer than ten large deals, showcasing a persistent capital clustering at the top end of the market. Underpinning this structural shift is the performance of the "Health Tech 2.0" cohort. This group, which includes companies like Waystar, Tempus AI, Hinge Health, Omada Health, Caris Life Sciences and HeartFlow, represents platforms that combine sustainable, high-velocity growth with clear operating leverage and robust data assets. Market Segment 2025 Equity Performance Market Cap Representation Core Valuation Multiplier Strategic Outlook Health Tech 2.0 Index Rose 18% in line with S&P 500 (+18%) and NASDAQ (+23%). Represents 30% of the $121B total market cap of active public players. High-growth, data-rich precision medicine and enterprise infrastructure platforms. Rapidly closing the 10-15% "Trust Gap" with general Cloud SaaS as platforms demonstrate 60%+ growth with positive free cash flow (FCF). Health Tech 1.0 Index Remained essentially flat throughout the year. Represents legacy companies that completed public offerings prior to the end of 2021. Legacy virtual care, commoditized point solutions, and consumer-facing health apps. Persistent valuation compression due to high customer acquisition costs, churn, and lack of integration into core hospital workflows. This structural divergence highlights that generic digital health platforms are experiencing multiple compression. Concurrently, premium platforms that leverage proprietary datasets and clinically validated machine learning models are successfully command valuation premiums. The market is no longer pricing technology based on growth projections alone; instead, it utilises a multi-dimensional pricing model that balances financial performance with structural defensibility. The Repricing of Cash Flows: Valuation Multiples in 2026 Transaction pricing in early 2026 is governed by the "Rule of 40 + Data" framework, which demands that companies balance growth with operational profitability while demonstrating clear control over defensible, proprietary data assets. Legacy SaaS metrics have normalised from their historic highs. Across publicly traded healthcare services and software companies, the median enterprise value-to-EBITDA (EV/EBITDA) multiple declined to approximately 11.5x in 2026, down from 14.5x in the prior year. However, this broad normalisation masks a deep divergence between essential, technology-enabled infrastructures and non-differentiated point solutions. Rule of 40 = Year over Year Revenue Growth Rate 40%+ EBITDA Margin When a platform meets this threshold and possesses a proprietary, clinically validated dataset, it achieves the premium "Rule of 40 + Data" tier, allowing it to bypass the baseline market multiples. Conversely, sub-scale or unprofitable software assets without clear technical defensibility have been compressed to multiples of 2.5x to 4.0x revenue, placing them in distressed or fire-sale territory. Sub-Sector Category Target Scale (EBITDA / Revenue) EV / Revenue Multiple EV / EBITDA Multiple Primary Pricing Dynamics & Infrastructure Premiums Premium AI & Data Platforms Scale-independent; high-growth clinical assets. 6.0x – 12.0x+ 15x – 20x+ Driven by proprietary clinical datasets, validated AI models, and deep integration within the EHR system of action. AI-First Drug Discovery Early-stage to mid-market; high therapeutic utility. 8.0x – 15.0x N/A Driven by high "bio-bucks" milestone potential and the looming patent cliffs of blockbuster therapeutics like Keytruda and Eliquis. Value-Based Care (VBC) Mid-to-large-scale clinical operators. 5.5x – 7.5x 12x – 15x Driven by demonstrable, data-proven return on investment (ROI) for commercial payers and successful management of high-cost chronic conditions (Oncology, Cardiology). Medtech (Software & Digital Health) $5M – $10M EBITDA scale. $3M – $5M EBITDA scale. $1M – $3M EBITDA scale. 4.0x – 6.0x 14.4x. 10.2x. 8.2x. Command strong pricing leverage matching private equity's preferred roll-up scale; targets exceeding $10M in revenue receive a 1.5x–2x step-up in multiples. MedTech / Hardware & Devices $5M – $10M EBITDA scale. $3M – $5M EBITDA scale. $1M – $3M EBITDA scale. 3.5x – 5.5x 10.4x. 8.3x. 6.7x. Dependent on MDR/IVDR compliance, hardware patents, and clinical barriers; companies with ancillary revenue streams (imaging, ASC ownership) command a 25–40% premium. General HealthTech SaaS Mature mid-market software players. 4.0x – 6.0x 10x – 13x Driven by predictable B2B contract unit economics, low customer churn rates, and stable annual recurring revenue (ARR). Sub-scale or Unprofitable Assets Pre-revenue or high-burn software targets. 2.5x – 4.0x N/A Characterised by unsustainable capital burn rates, lack of proprietary IP, and minimal clinical integration. These valuation ranges show that scale and revenue diversity play a critical role in pricing. Private equity consolidators and strategic health systems heavily favour mid-market operators in the $3 Million to $10 Million EBITDA range, utilising them as anchor platforms to execute buy-and-build strategies. Furthermore, targets that diversify their revenue streams by integrating ancillary clinical components, such as diagnostics, specialised imaging networks, or Ambulatory Surgery Center (ASC) ownership, achieve a 25% to 40% premium over peer organisations that are restricted to professional clinical fees. This premium reflects the high strategic value of owning end-to-end clinical data streams rather than operating as a transactional service provider. Dissecting the AI "X-Factor": Wrapper vs. Moat Dynamics The central diligence question for corporate development teams has evolved from verifying whether a target utilizes machine learning to auditing the structural depth of its AI integration. The private markets have moved past superficial "AI-enabled" marketing labels. Instead, they apply a strict analytical framework to separate low-defensibility "AI Wrappers" from high-value "AI Moats". The scale of this shift is visible in venture capital flows: by 2025, artificial intelligence platforms captured 55% of all digital health venture funding, up from 37% in 2024, 33% in 2023, and just 29% in 2022. For every dollar invested in artificial intelligence globally, $0.22 is now deployed directly to healthcare AI startups, representing a capital allocation that outpaces healthcare's baseline share of 18% of US GDP. To evaluate whether a target commands a genuine competitive moat or is merely a wrapper around third-party APIs, buyers employ the four pillars of the Health AI X-Factor framework: AI X-Factor Pillar Technical Mechanism M&A Valuation Impact Strategic Imperative Continuous Hyper-Growth Velocity Transitioning from pilot programs to full-scale enterprise deployments. Commands premium revenue multiples (8.0x – 12.0x+). Scaling to $100M+ ARR within five years compared to the 10+ year trajectory of legacy software companies. Revenue Durability & Defensibility Proprietary clinical databases, specialized algorithms, and verifiable clinical feedback loops. Protects against rapid commoditisation; eliminates 18–24 month regulatory bottlenecks. Building auditable pipelines, such as mapping generated text back to source clinical conversations to eliminate LLM hallucinations. Operational Capital Efficiency Enhancing clinician productivity by automating administrative workflows to drive ARR per FTE expansion. Expands gross margins to software-like levels (~80%), accelerating path to positive EBITDA. Reducing manual clinical documentation, scheduling, and billing workflows that historically consume 30% to 50% of physician time. EHR-Native Workflow Integration Transitioning point solutions into comprehensive systems of action embedded in Epic or Oracle Cerner. Eliminates the standard 20-30% "point solution discount" applied to standalone applications. Utilising FHIR R4, TEFCA alignment, and clean DICOM support to ensure the platform sits directly within the active clinical interface. The primary risk associated with an AI wrapper is its structural vulnerability to big tech platforms and direct API provider updates. Wrappers typically lack access to proprietary clinical feedback, leaving them exposed to high customer churn and pricing pressure. In contrast, a true AI moat is built on proprietary data, clinically validated models, and deep workflow integration. By embedding its technology within native EHR workflows and securing regulatory clearances, an AI-native platform creates high switching costs that protect its revenue stream from direct competition. The Regulatory Darwinism of Digital Health Regulatory readiness is a primary driver of enterprise value in modern healthcare M&A. Acquirers utilize regulatory compliance as a primary filter to separate high-risk software wrappers from institutional-grade clinical assets. For Software as a Medical Device (SaMD) and advanced clinical decision support systems, securing formal regulatory clearances acts as a powerful competitive barrier : The Valuation Impact of FDA Clearances: Securing a formal FDA 510(k) clearance or De Novo designation triggers a +0.5x to +1.5x uplift on a target's EV/Revenue multiple. This adjustment reflects the de-risking of commercial scaling and represents a regulatory barrier that protects the asset from rapid disruption by generalised software platforms. The MDR and EU AI Act Divide: In European and transatlantic transactions, the full enforcement of the EU AI Act for "high-risk" medical systems has created a binary pricing filter. Assets that possess existing Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR) certifications, coupled with "glass box" transparent AI models, command a 20% to 30% valuation premium. This premium is driven by their ability to provide immediate market entry for North American strategic buyers. Conversely, non-compliant assets face an 18-to-24-month regulatory bottleneck, resulting in severe valuation write-downs during diligence. Global Structural Variations: European digital health frameworks, such as Germany’s DiGA directory of approved digital health applications, have built high levels of consumer and provider trust through structured, state-sanctioned reimbursement paths. Furthermore, Europe's strict data localisation laws and patient consent regimes under the European Health Data Space (EHDS) initially slow clinical AI training speeds. However, once cleared, these barriers create highly defensible geographic moats that shield approved platforms from external competition. These regulatory dynamics demonstrate that compliance has transitioned from a backend operational concern to a front-end valuation driver. Software developers that bypass clinical trials or avoid formal regulatory pathways to accelerate launch timelines face significant multiple compression during M&A events. Acquirers are increasingly unwilling to subsidise a target's regulatory debt, reflecting a broader market shift toward clinical validation and rigorous data governance. Wrapper or Moat? How AI Is Re-Pricing HealthTech M&A Landmark Case Studies: Validation of the Architectural Premium The repricing of digital health assets is best understood through several landmark transactions that highlight the value of clinical validation, workflow integration, and operational scale. Case 1: Abridge (Scaling via EHR Integration and Verification) Abridge’s capital history and operational scaling illustrate the high value placed on native workflow integration and clinical trust. The platform’s valuation trajectory shows rapid appreciation, climbing from an estimated $850 Million in mid-2024 to a $2.75 Billion valuation in February 2025 during its $250 Million Series D round. This was followed in June 2025 by a $300 Million Series E round led by Andreessen Horowitz that valued the company at $5.3 Billion, with a subsequent $316 Million Series E extension closing in April 2026. Abridge’s commercial expansion is driven by its ability to address clinician burnout. Its technology automates 91% of medical note creation, saving clinicians an average of two hours per day in clinical documentation. To mitigate the risk of large language model (LLM) hallucinations, Abridge developed its proprietary "Linked Evidence" technology. This system maps every word in a generated clinical summary back to the source audio, creating a fully auditable trail that establishes trust with enterprise clinical administrators. The platform’s growth is further supported by its deep, native integration within the Epic EHR interface, allowing clinicians to generate summaries in under 30 seconds. This workflow integration enabled Abridge to scale to over 150 enterprise health systems by mid-2025, capturing over 50 Million medical conversations annually. Its deployment at UPMC, which scales the platform to 12,000 clinicians across 40 hospitals, represents a key proof point for multi-setting enterprise clinical AI. Abridge has also expanded its addressable market by integrating real-time prior authorisation with high-volume payers and partnering with medical journals (JAMA and NEJM) to deliver peer-reviewed medical search directly at the point of care. Case 2: Commure & Athelas (Consolidating the Digital Operating System) The October 2023 merger of Commure and Athelas valued the combined entity at $6 Billion, supported by a $70 Million investment from General Catalyst. The combined platform achieved a post-merger run-rate of $110 Million, which grew to $150 Million by the end of 2023, and subsequently secured a $70 Million funding round in 2026 that valued the consolidated entity at $7 Billion. The strategic rationale for the merger was to move away from isolated clinical point solutions toward an integrated, end-to-end healthcare operating system. Commure integrated PatientKeeper (which it acquired from HCA Healthcare in 2021) with Athelas’s AI-enabled Revenue Cycle Management (RCM) and Remote Patient Monitoring (RPM) modules under a single interface (CommureOS). By combining clinical scribing, automated billing, and home-based patient monitoring within a single EHR-integrated platform, the combined company created an enterprise system of action. This unified architecture has built deep relationships with hospital operators like HCA Healthcare, protecting Commure's revenue stream from displacement by single-feature software tools. Case 3: R1 RCM and Phare Health (Automating the Billing Plumbing) In October 2025, R1 RCM acquired London-based Phare Health, integrating the target’s clinical reasoning engines into its R37 AI Lab (which was co-developed with Palantir Technologies in March 2025). Phare Health specialises in advanced AI tools for inpatient medical coding and pre-bill Clinical Documentation Improvement (CDI). The acquisition represents a strategic move to secure back-office healthcare infrastructure. Phare’s technology automates the translation of unstructured clinical notes into highly accurate billing codes, helping providers capture full reimbursement while reducing administrative costs. By bringing Phare's technology into the R37 AI Lab, R1 RCM expanded its agentic AI capabilities across its established client base, protecting its core billing contracts from technological disruption. Buyer Dynamics and Structuring to Mitigate AI Risk The profile of active buyers in the HealthTech market has a significant impact on valuation multiples and transaction terms. Corporate strategic buyers (such as pharmaceutical companies and medical device conglomerates) are currently outbidding financial sponsors. Strategics paid 20% to 40% higher multiples than private equity firms in 2025, seeking to fill product gaps, capture clinically validated algorithms, and secure regulatory barriers to defend their core businesses. This strategic demand is reflected in the transaction data. Corporate strategic buyers accounted for 86.3% of Completed transactions in 2025, with a primary focus on therapeutics and technology-enabled services. Private equity firms and financial sponsors represented an 11.7% share, focusing primarily on medtech roll-ups, physician practice management (PPM) consolidations, and stable outpatient services. Concurrently, 2021-vintage private equity funds are reaching the end of their typical five-year investment cycles. This timeline has created a "use it or lose it" dynamic, forcing PE firms to deploy remaining dry powder and driving high transaction volumes in early 2026. The Pharmaceutical Platform Blueprint The strategic premium paid by corporate buyers is highly visible in the biopharmaceutical sector, where Q1 2026 marked a shift from isolated AI pilot programs to permanent, multi-billion-dollar platform commitments. Pharmaceutical companies are embedding AI directly into their core research and clinical trial development architecture : Eli Lilly's Infrastructure Commitment: Lilly co-invested over $1 billion with NVIDIA to build an AI co-innovation lab using supercomputing infrastructure. This was coupled with a $2.75 Billion platform collaboration with Insilico Medicine and the expansion of TuneLab, a federated AI model network trained on over $1 Billion of proprietary clinical data. Bristol Myers Squibb (BMS) Portfolio Integration: BMS executed four distinct AI partnerships in Q1 2026.These include integrating Immunai for patient stratification, Microsoft’s FDA-cleared radiology algorithms for clinical trials, and Evinova's agentic AI to optimise clinical trial designs. Daiichi Sankyo Selection Engines: Daiichi Sankyo partnered with BostonGene and Tempus to apply clinical digital twins and biomarker discovery models (such as Tempus's PRISM2 model) to improve patient selection for clinical trials. These transactions demonstrate that pharmaceutical strategics are paying premiums to acquire federated AI architectures that help reduce clinical trial failure rates. Bridging Valuation Gaps via Structured Earnouts To complete transactions in a highly disciplined market, buyers are utilising structured earnouts to manage technology risks and bridge valuation gaps. The prevalence of earnouts has grown significantly, with earnouts included in 33% of Completed transactions, up from 20% in 2021. Most earnouts are structured over a one-to-three-year performance window. To minimise post-transaction disputes, modern structures prefer objective, verifiable metrics—such as adjusted EBITDA or specific clinical trial clearances—over raw revenue targets. A standard 30% earnout structure in a healthcare technology transaction is illustrated below: Total Agreed Valuation = $10,000,000 Upfront Cash Payment (70\%) = $7,000,000 at closing Deferred Earnout (30\%) = $3,000,000 tied to future EBITDA performance. Target Baseline EBITDA = $2,000,000 annually over a 3-year measurement period. Annual Earnout Cap = $1,000,000 Year 1 Performance: The target achieves $2.1 M EBITDA, exceeding the baseline target and triggering a full $1,000,000 earnout payment. Year 2 Performance: The target achieves $1.5 M EBITDA (75% of target), resulting in a pro rata earnout payment of $750,000. Year 3 Performance: The target achieves $1.0 M EBITDA (50% of target), resulting in an earnout payment of $500,000. Final Transaction Outcome: The total earned purchase price is $9,250,000. This structure aligns post-close incentives, mitigates overpayment risks for the buyer, and allows the seller to capture full enterprise value upon demonstrating the scalability of their platform. Comprehensive AI Transaction Due Diligence Matrix To mitigate integration risks and validate target valuations, acquirers must execute rigorous clinical, financial and regulatory due diligence. Diligence Domain Critical Auditing Area Risk Mitigation & Valuation Impact Key Regulatory Reference Metrics Clinical Validation Peer-reviewed publications, randomized controlled trials (RCTs), and real-world clinical outcomes. Confirms model safety; prevents downstream product liability claims. Evaluation of model training datasets; verify bias-testing protocols and clinician-in-the-loop oversight. Data Governance & Security Comprehensive audit of historical HIPAA risk assessments and data access logs. Prevents False Claims Act liabilities; ensures target has secure, compliant data access. Active Business Associate Agreements (BAAs) with third-party cloud and IT providers. Revenue Cycle Management (RCM) Scrutiny of historical billing patterns, denial trends, and coding accuracy. Prevents False Claims Act liabilities and downstream reimbursement adjustments. Random chart audits to compare clinical notes against billed codes; analyze claim denials by CPT/HCPCS code. Payer & Contract Integration Map payer concentration; identify "change of control" renegotiation clauses. Protects historical revenue streams; mitigates risk of post-close contract terminations. Calculate effective net yields by accounting for historical denial rates and payer withholds. EHR Native Integration Mapping and verification of network architecture and real-time clinical workflows. Validates high switching costs; confirms platform is an integrated system of action. Verification of FHIR R4 API compatibility, TEFCA alignment, and native EHR-native real estate. Executing this structured due diligence matrix allows corporate development teams to identify hidden liabilities, refine transaction structures and ensure that premium valuations are backed by defensible operational moats. Strategic Conclusions and Outlook The repricing of HealthTech M&A has established a clear division between shallow software wrappers and defensible clinical operating systems. Standalone point solutions that increase administrative complexity face continuing valuation pressure. Conversely, integrated, EHR-native platforms that automate workflows, improve margins, and maintain strong compliance moats command significant premiums. For digital health founders, long-term value creation depends on clinical validation, regulatory readiness, and moving away from single-feature software models toward integrated enterprise solutions. For private equity and strategic buyers, success in this market requires executing deep, clinical due diligence, structuring performance-linked earn outs, and prioritising platforms that sit directly within core clinical and financial workflows. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Sanviva Case Study: Operational and Regulatory Dynamics of Axcel’s Pan-European MedTech Distribution Consolidation The execution of private equity buy-and-build strategies within the highly fragmented European medical technology distribution sector has reached a new level of scale and complexity. On June 2nd 2026, Nordic private equity firm Axcel announced the simultaneous acquisition of four distinct regional distributors to establish Sanviva, a newly consolidated European medical device distribution network. By pulling Apodan (Denmark), PartnerMed (Norway), AllweCare Medical (Netherlands), and XboXLab (Sweden) into a unified platform, Axcel is building a single, pan-European gateway. This consolidated platform, headquartered in Copenhagen, Denmark, establishes an immediate footprint across six European countries: Denmark, Sweden, Norway, Finland, Belgium and the Netherlands, operating with an initial workforce of approximately 60 employees. The overarching strategy of the platform, under the leadership of newly appointed Group CEO Andreas von Scholten, is to act as a highly specialised local commercialisation partner for global medical device manufacturers and original equipment manufacturers (OEMs). By providing direct access to multiple regional healthcare markets through a single partnership, Sanviva removes the need for OEMs to build out expensive, country-by-country sales forces or independently navigate local regulatory and public tendering frameworks. Transaction Architecture and Private Equity Fund Dynamics The consolidation of Sanviva was financed through Axcel Elevate I, a lower mid-market fund that held its final close at its oversubscribed hard cap of €459 Million in November 2025. This fund operates alongside Axcel’s larger mid-market vehicles, such as the €1.3 Billion Axcel VII fund, and specifically targets high-growth enterprises within the technology, business services, and healthcare sectors across Northern Europe. The transaction was formally completed in March 2026, marking the platform's initial deployment alongside other early-stage fund investments such as the Norwegian financial technology firm KapitalKontroll. Dimension Details Source Sponsoring Private Equity Fund Axcel Elevate I Various Fund Size & Closing €459 Million (Closed at hard cap, November 2025) Various Transaction Completion Date March 2026 Various Formal Platform Launch Date June 2, 2026 Various Sponsoring Firm Total Capital Over €4.8 billion raised across nine funds since inception Various Fundraising Advisory PJT Park Hill (Global Advisor), Kirkland & Ellis (Legal Counsel) Various Lead Transaction Counsel Vinge (M&A, FDI, and Corporate Commercial teams) Various Operating Executive Leadership Andreas von Scholten (Group CEO, ex-Coloplast, Zoetis, Grobest) Various The organisational leadership of the Elevate fund includes Christian Schmidt-Jacobsen, who has served as Axcel's Managing Partner since 2016 and retains direct responsibility for the Elevate strategy. This operates in parallel with a wider leadership transition within the firm, which saw Christian Bamberger Bro assume the role of Managing Partner in the first half of 2026. The execution of the Elevate investment mandate was further strengthened by the addition of Johan Lundén as a Swedish-based Partner in Spring 2026, bringing fifteen years of private equity experience from Trill Impact and Nordic Capital. The transaction team for the Sanviva platform also included Partners Kasper Olesen and Jacob Drakenberg Walberg, who actively led the deal execution. On the transaction advisory side, the Swedish business law firm Vinge acted as the primary legal advisor to Axcel. Vinge deployed a multidisciplinary team led by M&A specialists Christina Kokko, Egil Svensson, Ida Appelgren, Manon de Cooman, and Lina Björkman. Corporate commercial guidance was provided by Christoffer Nordin, while regulatory clearances under increasingly stringent Foreign Direct Investment (FDI) regimes were managed by Dagne Sabockis and Julia Rydin, with logistical transaction support coordinated by Filippa Bergkvist. Comprehensive Profiles of the Acquired Entities The foundational strength of Sanviva is derived from the distinct geographic footprints, commercial relationships, and specialized capabilities of the four consolidated distributors. Each target represents a localised market leader with historical roots in its respective domestic territory. Acquired Company Core Geography Operational Scale Specialized Product Portfolio Key Regulatory & Logistics Assets Sources Apodan A/S Denmark 14 employees; Est. $5.9M revenue Wound care, compression systems, hygiene, diagnostics DS/EN ISO 13485 certified; MDR compliant; Hørsholm office Various PartnerMed AS Norway ~10 employees Wound care, disinfection, hygiene consumables Licensed pharmaceutical wholesaler; Fredrikstad HQ Various AllweCare Medical B.V. Netherlands 11–20 employees; Est. $1.45M–$5.7M revenue Ostomy care (LaproCare), silicone scar dressings (ScarView) EUDAMED SRN NL-MF-000004379; Heteren facility Various XboXLab AB Sweden ~15 employees In vitro diagnostics (IVD), molecular and point-of-care testing Gothenburg 3PL (Medical Log Point); NSG technical partnership Various Apodan A/S Apodan A/S was founded in Kastrup, Denmark, by John Andreasen, initially importing and distributing active pharmaceutical ingredients to Danish pharmacies that manufactured localised medicines. In the 1970s, the company expanded into pharmaceutical packaging, subsequently establishing the Apodan PharmaPackaging brand to supply pill jars, vials and containers across the Nordic region. Following ownership by the Vind family and a small group of employees in the mid-1990s, the current owner Morten Lodberg Petersen joined the company in January 1997, overseeing a generational transition and the acquisition of moving aid manufacturer Immedia A/S in 1998. Apodan relocated to Hørsholm, Denmark, in 2017, and has focused its modern business model on four core areas: patient and surface hygiene products, specialised wound care, compression therapy systems, and clinical diagnostic equipment. The firm holds DS/EN ISO 13485 quality certification, is fully compliant with the European Medical Devices Regulation (MDR) and operates with a highly specialised team of 14 employees, including registered nurses and engineers, generating estimated annual revenues of $5.9 Million. During the COVID-19 pandemic, Apodan acted as a critical supply partner to the Danish national healthcare system by delivering diagnostic tests and medical hygiene consumables. PartnerMed AS PartnerMed AS was incorporated in Norway in June 1998, operating from its corporate headquarters in Fredrikstad. The company is led by CEO Trine-Lise Setterberg Andersen alongside Operations Manager Lasse Setterberg Andersen and Business Process Manager Siri Risvik Engen. PartnerMed acts as an authorised wholesale distributor of medical and pharmaceutical goods, specialising in wound care supplies, hospital disinfection systems, and clinical hygiene products. The company maintains a lean operational structure of approximately ten employees. It has built deep commercial penetration within Norwegian public hospitals, municipal nursing homes, and clinical practices, navigating the highly centralised public purchasing channels of the Norwegian state. AllweCare Medical B.V Operating from Heteren in the Gelderland region of the Netherlands, AllweCare Medical B.V. was founded in 2014, with its manufacturing arm, AwC Manufacturing B.V., established in 2016. Led commercially by Marketing Director Ton Mulder, the company employs between 11 and 20 staff, with annual revenues estimated between $1.45 Million and $5.7 Million. AllweCare represents a key strategic asset for the Sanviva platform due to its integrated manufacturing capabilities, holding registered manufacturer status under EUDAMED Actor ID NL-MF-000004379. The company's proprietary product lines include ScarView, a broad portfolio of medical-grade silicone dressings and gels designed to treat hypertrophic and keloid scars, alongside LaproCare, a specialised range of ostomy pouches and related accessories. AllweCare’s commercial channels span both high-volume business-to-business distribution and direct-to-consumer pharmacy reimbursement networks in the Benelux region. XboXLab AB XboXLab AB was established in Höllviken, Sweden, in 2016 by Peter Blom and Christer Lidén, who both brought over thirty years of clinical laboratory distribution experience to the venture. The firm expanded its operational footprint by launching a Norwegian subsidiary (XboXLab AS) under Managing Director Henning Jansen in 2019, and a Finnish subsidiary (XboXLab Oy) under Managing Director Jussi Kontturi in 2020. In 2020, the group also acquired Medic24, a specialised Nordic point-of-care (POC) diagnostics business. XboXLab operates a highly efficient, asset-light business model utilising specialised external partners. Its physical logistics are outsourced to Medical Log Point, which provides 1,250 square meters of modern warehouse space, including 310 square meters of specialized cold storage in Gothenburg, Sweden. For technical equipment maintenance, calibration, and support, XboXLab partners with Nordic Service Group, which deploys over 75 field engineers across the Nordic countries. XboXLab’s clinical focus covers in vitro diagnostics (IVD), immunohematology, immunology, molecular biology, and point-of-care testing systems, monitoring public laboratory tenders daily across Sweden, Norway, and Finland. Regulatory Frameworks and Market Access Barriers The consolidation of Sanviva is a direct response to rising regulatory demands and market access barriers across the European healthcare sector. The European medical technology market is valued at billions of euros, with healthcare spending averaging approximately 10% of gross domestic product (GDP) across European Union member states and per capita spending on medical technologies reaching €319 in recent years. However, capturing this market has become increasingly difficult for standalone, country-specific distributors. The primary barrier to entry is the ongoing transition to the European Medical Devices Regulation (MDR 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR 2017/746). These regulations divide medical devices and diagnostic tests into four distinct risk categories. They impose strict requirements regarding clinical evaluation reports, continuous post-market surveillance, EUDAMED registration, and complete supply chain traceability. For global OEMs, particularly those based in the United States or Asia, complying with these requirements requires a local authorised representative and extensive administrative resources. Even with a valid CE mark, manufacturers cannot freely distribute devices without navigating country-specific rules. For example, in Belgium, any medical device distribution requires formal notification to the Federal Agency for Medicines and Health Products (FAGG-AFMPS), alongside strict customs clearances requiring physical declarations of conformity and batch certifications. For a small distributor operating with fewer than twenty employees, the cost of employing dedicated regulatory officers to manage these requirements across multiple jurisdictions can quickly erode operating margins. By consolidating under the Sanviva platform, the acquired entities can centralise their regulatory and compliance departments. This allows them to spread compliance costs over a much larger revenue base, while offering global OEMs a single, fully compliant partner across the Nordics and Benelux regions. The Tendering and Public Procurement Matrix in Northern Europe Public procurement is the dominant purchasing mechanism in European healthcare, with approximately 70% of all medical devices and technologies bought through formal public tenders. However, the actual execution of these tenders is highly decentralised and fragmented by country and region. In Sweden, hospital procurement is divided across 21 independent regional authorities, alongside joint government framework agreements managed by the Kammarkollegiet via avropa.se. In Norway, public healthcare purchasing is centralized under Sykehusinnkjøp HF. This requires strict compliance with the national Doffin electronic database managed by the Norwegian Digitalisation Agency, which mandates public advertising for all tenders valued above NOK 1.4 million (~€120,000). In Finland, the landmark 2023 healthcare reform shifted public purchasing power to 21 regional wellbeing services counties, utilising platforms like Hilma and Hanki. In Denmark, purchasing is managed by five regional procurement bodies alongside Amgros, the central procurement agency for the country's public hospitals. Further west, the Belgian and Dutch markets present their own reimbursement and tendering complexities. In Belgium, the National Institute for Health and Disability Insurance (INAMI/RIZIV) maintains a strict list of reimbursable implants and invasive devices. This list requires brand-specific registration on "nominative lists" for high-cost devices, such as aortic valves, neuromodulation, and cardiovascular implants. Belgian public tendering is governed by strict financial thresholds: any purchase exceeding €200,000 requires a full European tender published in the Official Journal of the European Union, while purchases between €85,000 and €200,000 must be published in the Belgian Official Journal. In the Netherlands, outpatient devices and medicines are reimbursed through the complex Medicine Reimbursement System (GVS) managed by Zorginstituut Nederland. Additionally, individual Dutch university medical centres, such as Amsterdam UMC, Radboudumc, and LUMC, frequently run their own competitive tenders for medical equipment and consumables. Compounding this fragmentation is the rise of cross-border purchasing alliances. The Nordic Pharmaceutical Forum (NPF), established in 2015 by Amgros, represents Denmark, Norway, Sweden, Finland and Iceland. The NPF is actively working to establish joint purchasing mechanisms and integrate environmental sustainability criteria into tenders. Similarly, the BeNeLuxA alliance (comprising Belgium, the Netherlands, Luxembourg, Austria, and Ireland) has demonstrated the power of joint negotiations. This was highlighted by its collective pricing agreement for high-cost gene therapies like Zolgensma. For clinical suppliers, these shifting dynamics require a deep understanding of local tendering rules and platforms. Sanviva’s strategy is designed to address this challenge directly. By maintaining dedicated, local commercial teams in each country, the network can manage local relationships and monitor national tendering databases daily. At the same time, it can leverage its collective scale to meet the sustainability, security of supply, and clinical criteria demanded by modern public healthcare buyers. Platform Synergies and Value Creation Playbook The private equity investment playbook deployed by Axcel Elevate I relies on clear levers of operational optimisation, synergy extraction, and commercial expansion. Rather than acting as a passive holding company, Sanviva is designed to operate as an integrated platform. Portfolio Cross-Fertilisation and Cross-Selling The primary commercial growth driver is the immediate cross-selling of proprietary and exclusive product lines across the combined geographic network. Historically, AllweCare’s high-margin ostomy (LaproCare) and scar therapy (ScarView) portfolios were commercially confined to the Benelux region. Following the merger, these proprietary product lines can be introduced directly into the Nordic markets using Apodan's established clinical relationships in Denmark, PartnerMed’s networks in Norway, and XboXLab’s multi-country sales channels. Conversely, XboXLab’s sophisticated in vitro diagnostics and point-of-care testing systems can be integrated into AllweCare's existing distribution channels in the Netherlands and Belgium, introducing a high-growth clinical segment to those regions. Logistic Integration and Shared Services By merging four separate administrative and logistics networks, Sanviva can achieve significant cost savings. The platform's back-office functions—such as finance, human resources, regulatory compliance, IT, and legal advisory—can be centralised at the Copenhagen headquarters. On the logistics front, the platform can optimise its warehousing by consolidating regional inventories. XboXLab’s existing partnership with Medical Log Point in Gothenburg, which features over 1,250 square meters of modern warehousing and 310 square meters of specialised cold storage, provides an ideal logistical hub for the Nordic countries. Consolidating shipping volumes, standardising third-party logistics (3PL) contracts, and establishing shared cold-chain protocols reduces overall transportation costs and mitigates supply chain disruptions. Professionalising the Tender Management Engine Winning public tenders in Northern Europe is an administrative-heavy process that requires daily monitoring, specialised legal knowledge, and precise bid preparation. Individually, the acquired companies relied on small, localised teams to monitor platforms like Doffin (Norway), Hilma (Finland) and TendSign (Sweden). Sanviva can build a centralised tender management office equipped with dedicated bid writers and legal experts. This centralized team can analyze historical tender data, optimise pricing structures and draft highly compliant, value-based tender responses. Meanwhile, local representatives in each country, such as Apodan’s specialised nurses and clinical sales staff, can focus entirely on maintaining relationship touch points with hospital procurement officers and clinicians. This structure balances centralised bidding capabilities with necessary local market presence. Strategic Outlook and Future Expansion The launch of Sanviva by Axcel is a clear example of the ongoing professionalisation within the European medical device distribution sector. By executing a simultaneous quadruple acquisition through the Axcel Elevate I fund, the firm has quickly built a platform capable of handling the regulatory, logistical, and commercial complexities of modern healthcare markets. The strategic logic of the transaction is highly aligned with the current macroeconomic and regulatory trends in Europe, where the rising cost of MDR/IVDR compliance and the shift toward Value-Based Procurement favour large, integrated players over small, regional distributors. Looking ahead, Sanviva is well-positioned for further expansion. Having secured strong footholds in the highly stable and profitable Nordic and Benelux regions, the platform is likely to pursue additional bolt-on acquisitions. Strategic expansion into the DACH region (Germany, Austria, Switzerland), France, or the UK would further strengthen Sanviva’s value proposition to global medical device OEMs. By offering these OEMs a single, compliant and highly effective partner across the European continent, Sanviva is positioned to become a dominant pan-European force in MedTech distribution. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

The Paradigm Shift in Metabolic Health: Dexcom’s Strategic Acquisition of Nutrisense and the Convergence of Biosensing, AI and Coaching The landscape of continuous glucose monitoring (CGM) has reached a critical evolutionary inflection point. For more than two decades, the sector was defined by an intensive engineering competition focused on physical biosensor attributes: minimising sensor lag, improving mean absolute relative difference accuracy, reducing wearability profiles and ensuring seamless integration with insulin pumps and closed-loop systems. However, as physical sensors have achieved near-perfect accuracy and high clinical reliability, hardware has begun to undergo a process of commoditisation. This technological maturity has shifted the primary competitive front from the hardware layer to software, data interpretation, and behavioural intervention. This transition is exemplified by Dexcom’s acquisition of Nutrisense, announced during the American Diabetes Association’s Scientific Sessions (ADA 2026). By integrating a sophisticated nutrition coaching and behavioural modification platform into its core offerings, Dexcom is signalling that the future of the market lies in building full metabolic-health ecosystems rather than relying on sensor technology alone. The Strategic Imperative Behind Dexcom’s Acquisition of Nutrisense Dexcom’s acquisition of Nutrisense marks a deliberate move to expand its target market from traditional, high-risk diabetes management into preventative care, weight management and general wellness. Historically, Dexcom’s primary revenue engine has been prescribing CGMs to patients with Type 1 diabetes and insulin-dependent Type 2 diabetes. While highly profitable, this market represents only a fraction of the global population experiencing metabolic dysfunction, pre-diabetes, or general insulin resistance. Nutrisense has established itself as a leading player in the direct-to-consumer metabolic wellness space by bundling Dexcom's hardware with a comprehensive software app and access to human Registered Dietitians. The platform caters to individuals focused on optimising nutrition, athletic performance and body composition. By acquiring Nutrisense, Dexcom achieves several key strategic objectives, including the direct integration of dietitian services, transitioning to a high-margin subscription model and establishing preventative health pathways before patients escalate to insulin dependency. The transaction is expected to close in the coming weeks, subject to customary closing conditions and regulatory approvals, though the specific financial terms remain undisclosed. The programs offered by Nutrisense will continue to restrict eligibility, excluding individuals who take insulin or those who have a history of problematic hypoglycemia, thereby preserving its focus on early-stage intervention. This acquisition is flanked by two major announcements at ADA 2026 that reinforce Dexcom's pivot toward earlier-stage intervention. First, findings from the CONNECT study, a randomised controlled trial co-authored by Thomas W. Martens, MD, from the International Diabetes Center, were presented on June 6th, 2026, showcasing the clinical benefits of Dexcom CGM use in adults with Type 2 diabetes who do not use insulin. This trial has the potential to alter future clinical standards of care by proving that early CGM adoption improves glycemic control without pharmacological escalation. Second, Dexcom introduced a completely reimagined Stelo app experience, which received Food and Drug Administration clearance in May 2026. Select Stelo users were granted early access on June 5th, 2026, ahead of a full rollout scheduled for later in the summer. Stelo is Dexcom's over-the-counter platform designed for adults with Type 2 diabetes who do not use insulin, as well as general wellness seekers. The updated application launches with proactive artificial intelligence coaching, pattern recognition, and personalised weekly summaries designed to reveal the direct connection between glucose levels and physical sensations. Jake Leach, President and CEO of Dexcom, emphasised that these initiatives are designed to build a connected ecosystem that delivers real-time observations, personalised support, and behavioural coaching. The Broader Diabetes Technology and Ecosystem Landscape While the consumer wellness sector is rapidly expanding, the clinical diabetes technology market is undergoing its own software and hardware integration. The competitive landscape is shaped by deep hardware compatibility and automated insulin delivery (AID) algorithms, highlighting why physical sensor accuracy is no longer a standalone differentiator. Insulet recently updated the software algorithm for its Omnipod 5 patch pump, introducing a lower target glucose option of 100 mg/dL to provide clinical flexibility in diverse care settings. This update also improved automated alarm management, reducing patient interruptions and keeping users in automated delivery mode longer. Crucially, Insulet established compatibility between the Omnipod 5 and Abbott’s latest Freestyle Libre 3 Plus sensor, demonstrating that the market is moving toward cross-manufacturer interoperability. Concurrently, Beta Bionics shared real-world data from its iLet Bionic Pancreas, showing average baseline hemoglobin A1c improvements across its user database, and announced plans to launch its first insulin patch pump to compete directly with Insulet. Tandem is also set to file its tubeless insulin pump with the FDA during the current quarter of 2026, further crowding the clinical hardware space. In response to these developments, Abbott has actively expanded its clinical and consumer capabilities, securing a CE mark for a dual glucose-ketone sensor to provide advanced metabolic parameters. This clinical cross-pollination explains why Dexcom is investing heavily in software coaching; as clinical hardware interoperates and commoditizes, the software ecosystem that interprets data and drives patient adherence becomes the primary source of competitive advantage. Mapping the Competitive Landscape of Metabolic Health Ecosystems The race to establish dominance in the non-insulin-dependent metabolic health market has created a crowded and highly competitive landscape. Companies are utilising distinct strategies to combine hardware, software and coaching, resulting in a wide variation of pricing models and features. Platform Biosensor Hardware Integration Subscription Pricing & Access Cost Primary Target Audience Core Ecosystem Features Dexcom + Nutrisense Dexcom Stelo (non-prescription OTC) Financial terms of acquisition undisclosed ; subscription packages bundle Stelo hardware, glucose tracking, and dietitian coaching. Stelo hardware alone costs $89–$99/month. Prediabetes, non-insulin Type 2 diabetes, general wellness, and weight management. Personalized Registered Dietitian (RD) access, food/exercise logging, metabolic behaviour-change support. Abbott Lingo Lingo proprietary consumer biosensor (35mm diameter compared to the smaller 21mm profile of Libre 3) Learn: $49 (2 weeks/1 sensor); Build: $89 (4 weeks/2 sensors); Transform: $249 (12 weeks/6 sensors). Auto-renews every 12 weeks. Wellness-focused adults (18+) seeking metabolic optimization, excluding insulin users. Real-time glucose tracking, minute-by-minute bio-data, 30-minute live webinars with global nutritionists, and ketone tracking. Levels Health Integrates Dexcom G7, Stelo, or Freestyle Libre 3 Classic: $24/mo ($288/yr); Core: $42/mo ($499/yr); Complete: $167/mo ($1,999/yr). Sensors cost an additional $199/month. High-income wellness optimisers, longevity health advocates, and biohackers. Advanced proprietary AI (Meal & Day reviews) , Levels Labs blood testing ($99/visit or $178/two visits) , Season Health partner dietitians. Signos Dexcom Stelo Promo plans: $143.20/mo (6-month) to $225/mo (1-month) including sensors , or up to $449/mo without a subscription. Weight loss-focused consumers utilising real-time glucose bio-feedback. AI-driven prompts, food/weight/activity tracking, included dietitian consultation.Has optional Sustain Plan for app-only access. January AI Optional; can function entirely without hardware Subscription-based model utilising multi-omic integration. Health-conscious individuals seeking predictive physiological modelling. Multiomic predictive machine learning models, glucose response prediction across 32 million foods, 24/7 AI coach "Jan". This competitive landscape demonstrates a stark division in market approach. Abbott has chosen a direct-to-consumer strategy with Lingo, offering a highly accessible entry point of $49 per sensor. Despite its larger physical footprint of 35mm compared to the Libre 3’s 21mm, Lingo provides unique consumer-centric software features, ketone tracking, and introductory webinars with Abbott’s global nutritionists to help users lower their glucose levels. Meanwhile, Levels Health has built a premium, software-centric ecosystem that treats the CGM sensor as a secondary utility. Levels acts as an aggregator of biochemical data, charging an annual membership fee while outsourcing dietitian services to partners like Season Health. Levels has also integrated clinical diagnostics directly into its ecosystem through Levels Labs, which offers blood testing of five key metabolic markers (Fasting Insulin, ApoB, Triglycerides, Uric Acid, and HbA1c) to provide comprehensive metabolic tracking. January AI has bypassed hardware requirements altogether. By connecting user-authorised health records, wearable data, and food logs via Apple Health, January AI uses predictive machine learning to forecast post-meal glucose responses. This represents a highly scalable, software-only future that operates with or without a physical CGM. Signos and Nutrisense represent the hybrid baseline, tightly binding Dexcom's hardware with dedicated behavioural pathways focused on weight loss and metabolic coaching, respectively. The Paradigm Shift in Metabolic Health: Dexcom’s Strategic Acquisition of Nutrisense and the Convergence of Biosensing, AI and Coaching Human-in-the-Loop vs. AI-Guided Coaching: The Cost and Efficacy Equation As metabolic platforms scale, they face a critical architectural dilemma: whether to rely on human Registered Dieticians or automated AI coaching. This choice impacts both operating margins and clinical efficacy. Feature / Metric Human Registered Dietitian (RD) AI Health Coach (e.g., Levels AI, January AI's "Jan") Annualised Cost Estimate $1,800 – $4,800 per year (averaging $150–$400 per individual session). $120 – $600 per year (typically integrated into $10–$50/month app subscriptions). Interaction Frequency Extremely limited; typically monthly or bi-weekly scheduled sessions (12–24 touchpoints annually). Continuous, 24/7 real-time availability; daily push notifications and context-aware feedback (365 touchpoints annually). Data Processing Scope Manual analysis; constrained by human cognitive bandwidth to synthesize weeks of log sheets. Algorithmic analysis; scales to instantly cross-reference sleep, step counts, meal photos, and glucose curves. Clinical and Legal Scope Qualified to deliver complex Medical Nutrition Therapy (MNT) and manage comorbid pathologies. Legally restricted to sub-clinical behavioral modifications, lifestyle tracking and general guidance. Psychological Profile High emotional empathy, personal connection, and social accountability. High programmatic convenience, objective tracking, but lacks genuine human empathy. While human coaching provides deep empathy and clinical accountability, peer-reviewed clinical research highlights the unexpected efficacy of automated systems. A randomised controlled trial evaluated the performance of an AI-guided lifestyle coaching platform against standard conventional counselling in 96 participants with early prediabetes. The AI platform provided individualised behavioural feedback on physical activity, daily habits and nutrition utilising adaptive algorithms, whereas the control group received standard in-person clinical counselling every four weeks. Over the course of the study, the AI-guided cohort demonstrated a significantly greater reduction in haemoglobin A1c (mean change of -0.4%) compared to the conventional counselling cohort (mean change of -0.1%; $p=0.002$). The AI group also showed statistically superior improvements in fasting plasma glucose ($p=0.018$), BMI ($p=0.046$), and waist circumference ($p=0.031$). Furthermore, behavioral adherence scores and engagement frequency were markedly higher in the AI-guided group ($p<0.01$), indicating that continuous, low-friction digital interactions are highly effective at restructuring daily habits. Rather than viewing AI and human coaching as mutually exclusive, leading platforms are moving toward a hybrid operational model. In this architecture, AI handles continuous, high-scale data processing, meal photo analysis and real-time habit prompts. For instance, a user can text a photo of their meal through iMessage integrations, and the AI will analyse macro- and micronutrients, immediately advising the user on how to blunt a potential glucose rise. If a user's data shows complex anomalies, or if they require specialised clinical intervention, the platform escalates the care to a human Registered Dietitian. This hybrid approach optimises the cost-to-benefit ratio, allowing platforms to scale across millions of users via low-cost AI while reserving expensive human resources for critical, high-value clinical interactions. This is the precise operational framework Dexcom is building by combining Stelo's new AI pattern recognition features with Nutrisense's robust dietitian workforce. Clinical Validity and the Controversy of Non-Diabetic CGM Use The expansion of continuous glucose monitoring into healthy, non-diabetic populations has sparked an active debate within the endocrine and clinical research communities. Medical societies, including the American Diabetes Association, have established clear, evidence-based guidelines for CGM use in clinical practice. The ADA's Standards of Care recommend CGM use from the onset of diagnosis for all pediatric, adolescent, and adult patients with Type 1 or Type 2 diabetes who are on insulin therapies or on noninsulin regimens that present a risk of hypoglycemia. The guidelines also support CGM use in gestational diabetes and suggest considering its application in adults with Type 2 diabetes not on insulin to help them meet individualised glycemic targets. For individuals without diagnosed diabetes, however, clinical consensus has yet to be established, and interpretation guidelines are largely absent. This regulatory and clinical vacuum has split the medical community into two primary camps: those emphasising the preventative cardiovascular benefits of glucose monitoring and those warning against the psychological risks of medicalising healthy populations. The Case for Preventative Cardiovascular Health Proponents of non-diabetic CGM use point to emerging clinical research demonstrating that glucose fluctuations within standard normoglycemic ranges can have a profound impact on long-term health. A systematic review spanning literature from January 2020 to August 2025 evaluated CGM use in non-diabetic cohorts for guiding lifestyle modifications and preventing cardiovascular disease. The review showed that real-time glycemic data can identify subclinical metabolic dysfunction in specific populations, such as menopausal women and individuals experiencing obstructive sleep apnea. High glycemic variability in these groups was linked to key markers of cardiovascular risk, including blood pressure variability. Furthermore, the studies demonstrated that CGM data can optimise behavioural choices. For example, initiating a walk immediately before an individual’s personalised, postprandial glucose peak, rather than at an arbitrary time, significantly reduced overall postprandial glucose, insulin and C-peptide excursions. By mitigating these subclinical glycemic spikes, individuals can reduce systemic inflammation and vascular endothelial dysfunction, potentially avoiding the development of overt metabolic disease. The Case Against: Orthorexia Nervosa and Health Anxiety Conversely, many clinical psychologists and eating disorder specialists express concern over the widespread marketing of CGMs to healthy individuals. The primary concern is that continuous, high-frequency bio-feedback can foster health-related anxiety and trigger orthorexia nervosa. First described in the late 1990s by Dr. Steven Bratman, orthorexia nervosa is an eating disorder characterised by a pathological fixation on healthy, "pure," or clean eating. Unlike anorexia or bulimia, where the primary psychological driver is body image and weight control, orthorexia is driven by an obsession with dietary purity and optimal biological performance. The constant monitoring of blood sugar levels provides immediate, quantified reinforcement of this anxiety. Healthy individuals using these platforms may develop rigid rules, classifying complex carbohydrates or fruits as "bad" or "impure" because they cause normal, transient physiological glucose excursions. This can lead to the compulsive elimination of entire food groups, nutritional deficiencies, social withdrawal, and elevated levels of stress and anxiety. Clinical research indicates that those who study nutrition, exhibit perfectionist tendencies, or have a history of anxiety are particularly susceptible to developing these obsessive behaviors. Because orthorexia often presents as healthy behaviour, it is frequently reinforced by social circles and wellness apps, delaying clinical recognition and intervention. Conclusions and Strategic Outlook Dexcom’s acquisition of Nutrisense represents a major milestone in the evolution of digital health platforms. It signals that the physical sensor has matured into a utility, and that future market value will be concentrated in the software, behavioural, and interpretive layers that sit above the hardware. The competitive landscape is now divided into distinct strategies: Abbott is pursuing low-cost, mass-market consumer adoption with Lingo; Levels Health is offering premium, data-dense software subscriptions; and January AI is exploring hardware-free predictive modelling. For these platforms to capture market share, they must successfully navigate the balance between human-in-the-loop and AI-driven coaching. While human dieticians provide essential clinical safety and empathetic accountability, automated AI systems offer a continuous, cost effective and highly scalable solution that has been shown to deliver superior habit-formation and glycemic control. Moving forward, the primary challenge for the metabolic health sector will be clinical standardisation and psychological safety. Platforms must implement rigorous guardrails to prevent the development of orthorexia and health-related anxiety among healthy users. At the same time, they need to continue building robust clinical evidence, similar to Dexcom's CONNECT study, to demonstrate the long-term cost-effectiveness and preventative value of lifestyle-guided glucose monitoring. The platforms that can deliver scalable, behaviour-change coaching without causing psychological distress will be best positioned to lead this next era of preventative, personalised medicine. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 5th June 2026 The European HealthTech sector has seen a surge of momentum, highlighted by a massive growth round addressing one of the industry's biggest bottlenecks: administrative fragmentation and clinical workflow inefficiencies. The major developments shaping the European HealthTech landscape include: 1. Semble Secures £30M Series C to Redefine Care Orchestration The biggest headline comes from London-based Semble, which closed a £30 Million Series C funding round led by European growth investor Revaia, with participation from Partech, Mercia Ventures, and Octopus Ventures. The Problem: Healthcare providers across Europe are heavily weighed down by disjointed, legacy technology systems. This fragmentation burns out clinicians and slows down patient care. The Solution: Semble operates an open, interoperable clinical platform that integrates with over 1,200 external tools (including diagnostics, billing, and lab systems). It acts as a unified "system of action" to manage entire patient journeys and streamline workflows. The Scale: The platform has already powered care for over 10 million patients (roughly 1 in 6 people in the UK).The fresh capital will be used to scale their AI-driven care orchestration and expand heavily into large healthcare groups across the UK and France. 2. Strong Funding Momentum Backs Digital Health & AI A newly released sector report by Tech.eu (European Tech: The Big Picture) confirms that capital is concentrating into larger, highly commercialised rounds across biotech, medtech, and AI-enabled healthcare. The data highlights a clear geographical and strategic shift in where health tech dollars are flowing: Country Investment Volume Key Growth Drivers United Kingdom €2.5 Billion Leading the market with massive rounds in AI drug discovery, surgical robotics, and diagnostics. Switzerland ~€1.0 Billion Holding strong as the second largest hub, heavily backed by deep biotech innovation. Finland €881 Million Skyrocketed in prominence, heavily anchored by Oura Health (the smart ring maker), which achieved an $11 billion valuation. Investor Takeaway: While Series A deals are still robustly supporting early clinical platform development, late-stage capital is aggressively backing companies that have proven clinical utility and are actively scaling internationally. 3. The Clinical AI Benchmarking Shift While big-tech general AI models grab global headlines, European specialised medical AI labs are demonstrating superior clinical accuracy. Danish AI lab Corti recently made waves as its domain-specific medical coding model, Symphony, outperformed mainstream models like OpenAI and Anthropic by more than 25% in independent clinical accuracy benchmarks. This highlights a growing trend: European health systems are leaning toward hyper-specialised, highly regulated vertical AI solutions over general LLMs to ensure patient safety and compliance. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk >>>> The European MedTech sector has experienced a highly active week, dominated by fallout from the MedTech Forum 2026 in Stockholm, a major legislative clash over AI regulation, and fresh structural updates designed to make Europe a more attractive market for medical hardware and device innovation. The most significant MedTech developments shaping the market include: 1. The AI Act "Digital Omnibus" Backlash A major point of friction reached a head following the political agreement on the Digital Omnibus, which amends the landmark EU AI Act. The Conflict: MedTech Europe (the region's primary trade association) had heavily lobbied for medical technologies to have a single, sector-specific compliance pathway managed entirely under existing medical regulations. Instead, the final deal confirms that AI-enabled medical devices will remain subject to parallel, overlapping high-risk requirements from both the AI Act and the Medical Devices Regulation (MDR). The Industry Stance: Industry leaders expressed deep disappointment, stating the agreement adds "an unnecessary layer of complexity to a sector already operating under some of the world's most stringent oversight." Attention has now shifted toward using the ongoing, targeted revision of the MDR to salvage a workable solution and prevent severe market launch delays for smart medical devices. 2. Push for Radical Overhaul of the MDR & IVDR At the MedTech Forum, the overarching theme among European device CEOs was a collective anxiety over market conditions and a demand for structural predictability. Following the European Commission’s newly proposed revision package for the MDR and In Vitro Diagnostics Regulation (IVDR), MedTech Europe submitted its comprehensive 39-page position paper. The industry is aggressively backing proposals to simplify the rules, which the EU Parliament projects could save up to €3.3 billion annually(including €2.4 billion in wiped-out administrative bloat). Key areas of focus during this week's legislative debate include: The EMA Innovation Pilot: Industry leaders praised the European Medicines Agency's newly launched innovative device pilot for Class III and implantable devices, which acts as a precursor to a formal, US-style "breakthrough device" pathway. Regulatory Sandboxes: The introduction of EU-level regulatory sandboxes is being fast-tracked, allowing companies to test cutting-edge software and AI hardware in real-world environments without immediately hitting a wall of full conformity assessments. 3. Shift in Public Procurement Strategy: "Buy Better, Not Just European" A significant strategic pivot is underway regarding how European hospitals buy medical equipment. MedTech Europe CEO Oliver Bisazza issued a strong warning to EU policymakers against falling into raw protectionism. Currently, many European healthcare systems rely on price-only procurement, which heavily favors cheap imports and stifles local, high-quality hardware innovation. The industry is mobilising to pressure member states to rewrite procurement rules to prioritise value, clinical outcomes, and long-term supply resilience over the lowest sticker price. 4. The UK Responds with the "International Reliance" Pathway As the EU scrambles to fix its slow approval pipelines, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has moved decisively to capture market share. The MHRA published its draft Medical Devices (Amendment) Regulations 2026. Crucially, it introduces an international reliance pathway. This allows medical device manufacturers who have already secured regulatory clearance in trusted global markets (like the US FDA) to access the Great Britain market via a drastically fast-tracked, simplified review process. It represents a direct bid by the UK to attract global MedTech developers who are weary of Brussels' bureaucratic delays. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk